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Introduction to the 2-D Liquid Phase Protein Profiling Method Combined with 
Mass Spectrometry and Its Application to Studies of Cancer 
 
1.1 Introduction to Proteomics and Technologies  
 Cancer is a group of diseases in which cells are aggressive, invasive, and/or 
metastatic. Cancer remains a major public health challenge although there has been 
progress in detection and therapy. A substantial proportion of the US population will 
develop cancer during their lifetime (1) where many will die from the disease every year. 
In many of these cases, the cancer is not diagnosed and treated until cancer cells have 
already invaded surrounding tissues and metastasized throughout the body as shown in 
Figure 1. Many patients with breast, lung, colon and ovarian cancer have hidden or 
observable metastatic colonies and most conventional therapeutics are limited in their 
success once a tumor has spread beyond the tissue of origin. Current or future treatment 
strategies will have a higher probability of truly curing the disease if cancers can be 
detected when they are at their earliest stages, preferably in the premalignant state. 
Advances in the fields of genomics and proteomics have the capability to provide 
insight into the molecular complexity of the disease process and thus enable the 
development of tools to aid in treatment and also in detection and prevention when cancer 
is still at their early stage. Genomics technologies have made it possible to rapidly screen 
for global and specific changes in gene expression that occur only in cancer cells. 
Genomics-based approaches include the measurements of full sets of expression of 
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mRNA, such as differential display (2, 3), serial analysis of gene expression (4, 5), and 
large-scale gene expression arrays (6, 7). Although studies of differential mRNA 
expression are informative, they do not always correlate with protein concentrations (8, 9), 
where many changes in gene expression might not be reflected at the level of protein 
expression or function. Proteins are often subject to proteolytic cleavage or 
posttranslational modifications, such as phosphorylation or glycosylation. The field of 
proteomics represents a new paradigm of “reverse genetics” and enables the design of 
more informed and interpretable studies. 
Proteomics studies are the complete set of proteins found in a given cell type in 
any particular state. Proteomics targets the protein environment or proteome of a 
population of cells and can identify the changes that occur during a disease process at the 
protein level. The discipline of proteomics focuses on the large-scale identification and 
characterization of proteins through the measurement of protein expression under specific 
conditions from patient samples. The important tools critical to detection, diagnosis, 
treatment, monitoring, and prognosis in proteomics are the classification of molecules 
and the identification of biomarkers. Proteomic analyses of cancers by using 
classification and biomarker discovery techniques have provided new insights into the 
changes that occur in the early phases of tumorigenesis and represent a new resource for 
early-stage disease detection.  They can provide an early indication of the disease, to 
monitor disease progression, to provide ease of detection, and to provide a factor 
measurable across populations. Different combinations of methods have been developed.  
For many years, 2-dimensional polyacrylamide gel electrophoresis (2-D PAGE) 
followed by protein identification using MS has been the primary technique for 
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proteomic-based studies (10-12).  Proteins are separated first according to their isoelectric 
point and then submitted to a second separation based upon their mass (6, 13, 14). 2-D 
PAGE is still the method of choice for high-resolution protein separation and provides 
the best method to monitor protein modifications. However, the technique suffers from a 
number of shortcomings, such as limited loading capacity, inability to separate proteins 
with extreme pI values, difficulty generating reproducible gels, or the difficulty of 
resolving several classes of proteins, such as very basic proteins, small proteins, and 
hydrophobic proteins; therefore, only part of the proteome is uncovered by the 2-D 
PAGE approach.  
Currently, non-gel based technologies have been widely used for proteome 
analysis for cancer studies. Surface-enhanced laser desorption ionization (SELDI), is a 
technique based on the identification of proteome patterns that could be used as disease 
signatures. SELDI technology is based on the selective retention of proteins on modified 
array surfaces (15-17). When unbound proteins are discarded, proteins retained on the 
array are analyzed by MS, generating a specific pattern or profile of the analyzed 
proteome. Proteome patterns then are compared to decipher statistically significant 
differences in protein expression among different samples. SELDI is useful in high-
throughput proteomic fingerprinting of cell lysates and body fluids. 
Another approach for proteome analysis is protein arrays. Protein biochips are 
emerging in different formats. Several groups have been using high-throughput chip-
based analysis to study protein–protein, protein–DNA, and protein–RNA interactions 
(18-20). Typically, a specific protein is spotted through cross-linking to a chip surface, 
such as a glass slide, in a grid-like fashion, and samples are passed over the slide for 
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detection of interacting molecules. Another emerging protein microarray format involves 
the surface capture of proteins through antibodies, followed by MS (21). This technique 
allows one to semiquantitate the expression of a protein among patients or during the 
course of a disease. The mass information generates a fingerprint that can be compared in 
a database. High-throughput can be obtained because potentially thousands of 
addressable locations can be designed for a chip for protein capture.  
Finally, an important approach is the multidimensional protein identification 
technology which is based on gel-free separation (22-25). This technique combines 
separation of the generated proteins by liquid chromatography, enzymatic digestion of 
complex protein mixtures, and MS analysis. The methodology not only has greater 
reproducibility, but also has the ability to identify and quantify proteins, and the 
capability to compare results amongst different sets of experiments and samples. A major 
advantage of this technique is the detection of lower abundance proteins.  
Our laboratory has introduced and developed a useful strategy by combining 
multidimensional separation of the generated proteins by liquid chromatography with 
mass spectrometry to study changes in cancer cells. By this strategy, we can apply the 
differential protein mapping method to classify cancers and find the potential biomarkers 
for different groups of cancers. Chromatofocusing (CF), which fractionates proteins 
based upon pI in the first dimension, is used with nonporous silica (NPS) reversed-phase 
high-performance liquid chromatography (FP-HPLC) separation in the second dimension 
to achieve high resolution separation. Proteins are separated and mapped to generate an 
image of the cellular protein content. After the two dimensional separations, there are 
couple of different ways to apply the differential protein method in our lab. Firstly, 
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classification of the cancers and differentially expressed proteins can be obtained by 
analyzing the data based on the UV maps. Second, after the first dimension CF separation, 
RP-HPLC separation can subsequently be directly interfaced to ESI-TOF-MS to generate 
intact molecular weight information to create a map of the accurate MW versus protein pI. 
This mass mapping technique can also obtain differentially expressed protein information 
and help to apply the classification of the cancers. Third, we can also use the two 
dimensional separation fractions to produce protein microarrays, where we can obtain the 
information about classification and biomarkers. A key point of the differential protein 
mapping method is the production of substantial amounts of highly purified proteins 
isolated in the liquid phase, which provides an automated way to collect hundreds of 
proteins for subsequent enzymatic digestion and identification by mass spectrometry. The 
automation of the method allows reproducible comparison of many samples based upon 
separations monitored by UV detection, allowing direct comparison of samples to detect 
changes in the proteome. Relevant fractions can then be subjected to MS to identify the 
proteins of interest. The use of differential analysis limits the number of proteins that 
might require further analysis by mass spectrometry techniques.  
Mass spectrometry is the most important proteomic tool. From 2D-PAGE to gel-
free proteomics, mass spectrometry is universally used as the end technique for the 
identification of proteins by peptide mass mapping and by the sequencing of peptides 
using tandem mass spectrometry. The highly accurate mass measurement of peptides and 
proteins by mass spectrometry has revolutionized the field of proteomics. In our studies 
here, we used several different mass spectrometers, such as ESI-TOF-MS, MALDI-TOF-
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MS, QIT-TOF-MS, and LTQ. In the present study, we will describe some of the methods 
and experimental procedures used to accomplish this work. 
1.2 Separation Methods 
1.2.1 First Dimension Chromatofocusing(CF)  
 Chromatofocusing (CF) is a variant of ion exchange chromatography. It elutes ion 
exchangers by the mechanism of pH. In anion CF, proteins are bound to an anion 
exchanger at high pH. As the pH on the column decreases, protein positive charge 
becomes stronger and protein negative charge becomes weaker. pH conditions in the 
column eventually reach a point where a given protein's net interaction with the column 
becomes zero and it elutes. This anion exchange column based separation method has 
been selected and applied in our lab for the first separation dimension. Figure 1B shows a 
representation of a chromatogram. Proteins are loaded on the column at a high pH and as 
the titration proceeds, proteins with pI values greater than the pH will elute. Fractions are 
collected at a specified interval based on pH measurements. This pH-based protein 
separation method can rapidly fractionate large numbers of proteins and achieve 
separation of proteins in narrow (0.1) pH fractions. The use of online pH measurement 
and the column-based technique make it readily automated and easily interfaced with 
other liquid separations. 
1.2.2 Second Dimension Non-porous silica reverse phase HPLC 
 After the first dimension separation, each pI fraction from a whole cell lysate still 
contain a large number of proteins. Reverse phase HPLC was applied to the fractions as 
the second dimension to separate proteins to obtain sufficient resolution. Reverse phase 
HPLC is one of the most widely applied analytical techniques in the world which occurs 
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via a partitioning of analytes between a polar, liquid mobile phase and a non-polar 
stationary phase. Proteins are eluted using a gradient method according to their subtle 
differences in hydrophobicity. Figure 1 C is a representative RP-HPLC chromatogram. 
This NP RP-HPLC provides rapid and highly reproducible separation of proteins. The 
use of C18-coated, silica-based NP packing materials and small particle size (1.5µm) for 
the column results in improved resolution, improved protein recovery and highly efficient 
protein separations (26-28). 
 Beckman-Coulter has developed a system, the ProteomeLab PF2D which   
features separation by chromatofocusing in the first step, followed by RP 
chromatography in the second dimension. The system is shown in Figure 1A. The system 
is automated and allows separation of complex protein mixtures into several hundred 
fractions. Separation is followed by UV detection, allowing direct comparison of samples 
to detect changes in the proteome. In our work here, we mainly used this system. Data 
acquisition and fraction collection are controlled by an accessory PC. Relevant fractions 
can then be subjected to MS to identify the proteins of interest.  
1.3 Mass Spectrometry 
1.3.1 ESI-TOF-MS 
ESI is a popular ionization method for peptides and proteins primarily owing to 
its superior ability to interface with a multitude of liquid separation techniques from LC 
to capillary electrophoresis. In ESI, liquid is usually sprayed through a heated, high-
voltage capillary. Analyte is pumped through a capillary to form a “taylor cone”. The 
droplets expand through gas at atmospheric pressure, where the droplet undergoes size 
reduction by evaporation of solvent, so that charge density at the droplet surface increases. 
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When sufficient deformation and charge density electrostatic repulsion exceed the surface 
tension, the droplet becomes unstable and falls apart. It predominantly creates multiply 
charged analyte ions. The feature allows large analytes such as proteins to be measured in 
a mass analyzer within a limited mass range. Current ESI-TOF instruments permit the 
practical measurement of proteins up to 80 kDa with 100-400 ppm mass accuracy by 
surveying only a mass range from 0-5000 m/z.  
In this work, the Micromass LCT ESI-TOF-MS instrument was used to obtain 
mass and quantitation data on intact proteins. Figure 3a shows the scheme of the 
instrument design. The eluent from HPLC is readily interfaced with ESI-TOF-MS for 
analysis of intact protein molecular weight. Quantitative interpretation of multiply 
charged ESI data is carried out using maximum entropy deconvolution (MaxEnt) 
software.
 
This algorithm iteratively compares and minimizes differences between a 
“mock spectrum” and the original m/z data generating a parent spectrum (Figure 3b) that 
is most likely to result in the original m/z spectrum. Mass and intensity calculated in this 
manner can then be used for quantitative comparisons (Figure 3c). On-line separations 
with ESI-TOF-MS detection are described in greater detail in Chapters 2&3.  
1.3.2 MALDI-TOF-MS 
MALDI is commonly coupled with time-of-flight (TOF) mass analyzers. It is a 
very simple and robust method for protein identification. A protein or peptide sample is 
co-crystallized with an excess of a UV-absorbing matrix. Predominantly singly-charged 
analyte ions are created when the protein molecule mixtures are bombarded with intense, 
short duration bursts of laser radiation. MALDI mass spectra are easy to interpret because 
of their exclusively singly-charged ions. MALDI also shows a high degree of 
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compatibility with common biological buffers and contaminants minimizing the need for 
excessive sample cleanup prior to analysis. Furthermore, MALDI instruments are 
amenable to high-throughput approaches and spectra are generated with little sample 
consumption. MALDI-TOF instruments are capable of sensitivity as well as less than 10 
ppm mass accuracy with internal calibration for analysis of peptides. These 
characteristics of MALDI-MS have been applied to its use in peptide mass fingerprinting 
expression for protein identification.  
The Micromass TofSpec-2E is a compact high performance TOF mass 
spectrometer utilizing MALDI, which provides full mass spectra with high sensitivity 
over very wide mass ranges. Figure 4a shows the scheme of the TofSpec design. The 
Micromass Masslynx software package provides automatic instrument control as well as 
advanced data processing facilities. The mass fingerprint is searched against a protein 
database obtained by theoretical cleavage of protein sequences stored in databases. The 
protein solution eluting from the HPLC separation can be collected and each fraction is 
subsequently digested by trypsin. The digest from each protein peak can be further 
analyzed by MALDI-TOF-MS for protein identification based on peptide mass 
fingerprinting as shown in Figure 4b.  Work details are discussed in Chapters 2&3. 
1.3.3 QIT MALDI quadrupole ion trap-ToF  
In our work, we used the Shimadzu AXIMA-QIT system as a method for protein 
identification. The AXIMA-QIT is a hybrid quadrupole ion trap - reflectron time-of-flight 
instrument incorporating a matrix-assisted laser-desorption ionization (MALDI) source. 
MSn allows for multiple rounds of parent-ion isolation and fragmentation, making it ideal 
for detailed structural characterization of biomolecules, particularly oligosaccharides. 
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Samples mixed with a matrix are deposited onto the MALDI target and dried. A Nitrogen 
gas laser produces a pulse of UV light of <5ns duration at 337nm and is focussed to a 
spot less than 150µm diameter onto the target. The sample/matrix mixture absorbs the 
UV light resulting in a pulse of ions being ejected from the sample surface. These ions 
are accelerated and focussed by a series of electrostatic ion optics towards the ion trap. 
When all ions of interest are in the trap, appropriate electronics are activated and 
maintain the required RF voltage applied to the ring electrode. When ions are ejected 
from the trap, they enter a flight tube that is floated at the same potential as the extraction 
electrode. The energy spread is compensated for by an ion reflectron. Accuracy is 
dependent on the stability of extraction, floating and reflectron voltages and possible 
jitter on timing various events. Mass resolution is a function of energy spread which in 
turn is a function of cloud size and the same mass ions at the front and the back of the 
cloud will acquire different energies. The ion reflectron corrects the time-of-flight 
difference arising from this aberration. Figure 5a shows an overview of the system. 
Representative data is shown in Figure 5b. Work details are discussed in Chapter 4. 
1.3.4 LC-MS/MS 
We used the Finnigan™ LTQ™ system in our studies. The ThermoElectron 
Finnigan LTQ is a linear ion trap mass spectrometer equipped with an electrospray 
ionization source. A Michrom nano-HPLC system is interfaced to the mass spectrometer 
for automated LC-MS/MS analyses. This HPLC interface allows for separation of 
complex mixtures prior to on-line MSn analysis. The Finnigan LTQ MS detector is an 
advanced analytical instrument that includes a syringe pump, a divert/inject valve, an 
atmospheric pressure ionization (API) source, an MS detector, and the Xcalibur data 
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system. In a typical analysis, a sample can be introduced using a valve and an LC system 
fitted with a column (LC/MS). In analysis by LC/MS, a sample is injected onto an LC 
column. The sample is then separated into its various components. The components elute 
from the LC column and pass into the MS detector where they are analyzed. The data 
from the MS detector is then stored and processed by the Xcalibur data system. With ESI, 
the range of molecular masses that can be analyzed by the Finnigan LTQ MS detector is 
greater than 100,000 u, due to multiple charging. 
The LTQ has improved capacity and advantages such as improved trapping 
efficiency and scan speed when compared to a 3-dimensional trap. In addition, these 
features result in sensitivity increases that are approximately 100-fold higher than other 
mass spectrometers. The LTQ can be set up to collect full scan MS and MSn (n=2-10) 
data. Advanced scanning modes include data-dependent scans, zoom scans, and ultra 
zoom scans. Ion mapping experiments can be used to generate full scan, neutral loss, and 
parent ion maps. Both positive and negative ions can be detected. Figure 6a shows the 
scheme of the system overview. Work details are discussed in Chapters 4&5&6. 
1.4 Overview of the Dissertation 
 The work presented in this dissertation is focused on the interlysate studies of 
human ovarian serous carcinoma samples and breast cancer samples using differential 
mapping technique combined with mass spectrometry. Chapter 2 describes the initial 
study of 18 cell lines using the differential protein mapping method by UV map. This 
automated 2-D liquid fractionation system can classify the different samples according to 
their protein expression profiles. Potential marker bands used to classify subtypes of 
cancer can be identified using ESI-TOF-MS and MALDI-TOF-MS. As an outgrowth of 
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this initial study, the mass mapping technique was also applied to the ovarian serous 
carcinoma cell lines in Chapter 3. In Chapter 4, a more-in-depth profile of global protein 
expression patterns in 19 ovarian serous carcinoma tissue samples is presented. 
Molecular classification was applied and proteins that were differentially expressed in 
different groups were selected for identification by MALDI-TOF-MS or MALDI QIT 
TOF or LTQ MS. Studies were also applied to the membrane glyco-proteome using 
different breast cancer cell lines CA1a and AT1 in Chapter 5, which is a complimentary 
study for the soluble protein studies in chapter 2, 3 and 4. Multiple lectin extraction was 
used and differential proteins were identified using ESI-MS/MS. Chapter 6 describes the 
study of the classification of the humoral response using a two-dimensional liquid 





































































































Figure 1.2 A. PF2D system  
      B Representative 1st dimension chromatofocusing chromatogram: UV 280nm   
























































Figure 1.3 A. Schematic of Micromass LCT  
       B. Sample electrospray spectrum 
      C. MaxEnt deconvolution of mass spectrum 
200ul/min 2-27min for maldi



















































Figure 1.4 A Schematic of the Micromass TofSpec2E  












































Figure 1.5 A Schematic of the Shimadzu AXIMA-QIT TOF MS  
      B Example MALDI QIT-TOF-MS spectrum  





































































Figure 1.6 A Finnigan™ LTQ™ MS system 
      B Example LTQ MS spectrum  
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Classification of Cancer Cell Lines Using an Automated 2-D Liquid Mapping 
Method with Hierarchical Clustering Techniques 
 
2.1 Introduction 
 An important area in current cancer research is directed towards improving the 
molecular classification of cancer (1). This involves the ability to find markers, which 
can be used to differentiate cancers arising in the breast, lung, colon, prostate, and other 
organs from one another (2, 3). Moreover, various subtypes exist for cancers arising in 
many organs, each with different histopathology and ultimately very different clinical 
outcomes (4-6). It is essential to find markers that can be used to classify tumors with 
respect to organ of origin, benign versus aggressive behavior, and likely response to 
specific treatments (7). This ability to use molecular information to improve upon 
existing morphology-based tumor classification schemes would further the concept of 
personalized medicine. 
 Ovarian cancer is particularly problematic in that it comprises a heterogeneous 
group of tumors, many with poorly characterized precursor lesions. Worldwide, ovarian 
cancer is the sixth most common cancer in women with the highest incidence rates 
appearing in developed countries (1). Epithelial ovarian cancer, or ovarian carcinoma 
(OvCa), constitutes about 90% of all ovarian cancers and is divided into four major 
distinct subtypes (serous, mucinous, endometrioid, and clear cell) based on their 
morphological features.  Interestingly, each ovarian carcinoma subtype resembles normal 
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epithelial cells found elsewhere in the female reproductive tract derived from a common 
embryological precursor known as the coelomic mesothelium (5). For example, serous, 
mucinous, and endometrioid ovarian carcinomas display morphological features similar 
to normal epithelial cells lining the fallopian tube, endocervix, and endometrium, 
respectively.  Presently, ovarian carcinoma is managed clinically without consideration of 
morphology, yet there is growing clinical-pathologic and molecular evidence that the 
different subtypes may represent clinically, biologically and genetically distinct disease 
entities. 
 There are several strategies that can be used to classify cancers based upon either 
gene or protein expression. In particular, DNA microarrays have been used to 
characterize global gene expression patterns of cancer samples (1, 4). This technology 
has enabled the study of comprehensive gene expression profiles of large numbers of 
tumor samples, which can be used to classify cancers based upon characteristic gene 
expression patterns. In recent work, for example, Schaner et al used DNA microarrays to 
identify groups of genes that could distinguish ovarian from breast carcinomas, clear cell 
subtype from other ovarian carcinomas, and grade I and II from grade III serous papillary 
carcinomas (4). In related work, Perou et al were able to use gene expression signatures 
to define subclasses of breast cancer (8) and Sorlie et al were able to correlate differences 
in expression patterns of breast cancers with clinical outcome and identify subclasses 
having poor prognosis (9). In other work, Giordano et al were able to use gene expression 
profiles of adenocarcinomas of the lung, colon and ovary to demonstrate the ability to 
classify tumors in an organ-specific manner (3). Schwartz et al used gene expression 
patterns to classify the different subtypes of ovarian cancer and showed that these 
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patterns in ovarian adenocarcinomas reflect both the morphological features as well as 
the biological behavior (5). Numerous other studies have also used gene expression to 
classify various cancers and their subtypes and their relationship to one another (10-12). 
 An alternative means of classifying different types of cancers involves profiling 
the protein expression of cells or serum (7, 13). The use of protein expression may be 
most informative for classification of cancers since mRNA and protein expression from a 
given gene may be discordant and it is ultimately the protein expression that determines 
the function and structure of the cells. In addition, protein expression can be profiled 
from either tissues or serum. The traditional method for profiling large numbers of 
proteins from cells is 2-D gel electrophoresis (14). A number of studies using large 
numbers of quantitative 2-D gels for tumor classification have been performed for 
bladder, breast, lung, prostate and ovarian cancers (6, 7),  where, in general, benign and 
malignant tumors were identified by proteins that were differentially expressed and tumor 
stage classified by marker proteins that were up or down-regulated. Alaiya et al did 
extensive work on the classification of ovarian tumors where protein expression of 40 
tumor samples was evaluated using 2-D gels with hierarchical cluster analysis to 
distinguish borderline ovarian tumors from malignant and benign tumors (6). Other work 
by this group using quantitative 2-D gel electrophoresis identified protein markers that 
could classify benign, borderline and malignant tumors (15). In recent work Jones et al 
examined the use of laser capture microdissection (LCM) of human ovarian epithelial 
cells in tissue specimens followed by 2-D gel electrophoresis to identify proteins that 
change between invasive and noninvasive ovarian cancers (7). These differentially 
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expressed proteins could potentially be used to generate markers of early detection or 
therapeutic targets unique to the invasive cancer. 
 Although 2-D gel electrophoresis has been the most widely used technique for 
separating large numbers of proteins, there are still drawbacks that limit its utility as a 
general tool for profiling of large numbers of samples. The 2-D gel method is generally a 
slow, manually intensive technique that can require several days to run and stain. 
Moreover, the reproducibility of interlysate comparisons may be limited due to varying 
run conditions between gels where spots may become difficult to compare and 
quantitation may be limited. In addition, proteins are embedded in the gel requiring 
manually intensive procedures to excise the spots for further analysis by mass 
spectrometry.  
 An alternative strategy to rapidly classify large numbers of different types of 
cancers using protein expression profiling is 2-D liquid mapping of proteins (16, 17). 
This technique uses chromatofocusing as the first separation parameter followed by 
nonporous reversed phase HPLC as the second dimension to orthogonally map large 
numbers of proteins based on their pI and hydrophobicity respectively. Both dimensions 
of analysis use standard chromatography (HPLC) equipment designed to reproducibly 
handle large numbers of samples in the liquid phase. It also uses UV absorption for 
detection so that quantitative comparisons of protein expression can be performed 
between samples. The method has distinct advantages in automation in that all fractions 
are in the liquid phase and large numbers of samples can be run and protein maps 
obtained for easy differential comparisons. Moreover, because proteins elute in the liquid 
phase, direct interface with other methods such as mass spectrometry is readily achieved. 
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 In this work, we demonstrated the use of an automated 2-D liquid fractionation 
system for the liquid phase separation and mapping of the protein expression for eight 
serous ovarian cancer and three ovarian surface epithelium (OSE) cell lines. Hierarchical 
clustering analysis was used to classify the different samples according to their protein 
expression profiles showing that specific types of serous carcinoma cell lines tend to 
cluster together. Several other cell lines e.g., ovarian clear cell and endometrioid 
carcinoma and breast epithelial cell lines, were also fractionated and mapped by the 2-D 
liquid method and cluster analysis performed on a total of 18 samples. We compared our 
cluster analysis to results using oligonucleotide microarrays identifying some similarities 
and some differences in the observed clustering patterns. We could classify different 
types of cancers in addition to identifying potential marker bands to classify different 
subtypes of individual cancer using this methodology. The use of this method also limits 
the number of potential marker bands that may need to be identified by mass 
spectrometry. We also demonstrated that these samples could be run reproducibly and in 
an automated fashion using this method. 
2.2 Experimental Section 
2.2.1 Cell Culture and Sample Preparation  
A total of fourteen ovarian cell lines were applied in this study, which included 
eight serous, one clear cell, two endometrioid and three immortalized ovarian surface 
epithelial cell lines. Ovarian serous carcinoma-derived cell lines HOC-1 and HEY were a 
gift from L. Dubeau (USC School of Medicine, Los Angeles, CA); DOV13, OVCA420, 
OVCA429, OVCA432, and OVCA433 were a gift of D. Fishman (North-western 
University, Chicago, IL); PEO1 was a gift from T. Hamilton (Fox Chase Cancer center, 
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Philadelphia, PA). One ovarian clear cell adenocarcinoma derived cell line (ES-2) and 
two ovarian endometrioid adenocarcinoma cell lines (MDAH-2774 and TOV-112D) 
were obtained from the American Type Culture Collection. Ovarian surface epithelial 
cells expressing SV40 large T Antigen (IOSE-80 and IOSE-144) were a gift of 
N.Auersperg (University of British Columbia, Vancouver, British Columbia, Canada). 
HOSE-A (96.9.18), an OSE cell line immortalized with HPV16 E6/E7 was a gift from W. 
Lancaster (Wayne State University School of Medicine, Detroit, Michigan). The MCF10 
human breast epithelial cell lines were obtained from the Barbara Ann Karmanos Cancer 
Institute (Wayne State University, Detroit, MI, USA). Cells were cultured as previously 
described (18). All the cell lines were cultured under standard conditions in the 
Department of Pathology at the University of Michigan Medical School. The cells were 
maintained in DMEM/10% fetal bovine serum and 1% Penicillin/Streptomycin 
(Invitrogen, Gaithersburg, MD).  When monolayer cultures were 80-90% confluent, the 
cells were washed three times with phosphate buffered saline (PBS) and lysed in lysis 
buffer. Lysis buffer (90 µL/cm2) consisted of 6 M urea (INC Biochemicals, Cleveland, 
OH, USA), 2M thiourea (INC), 1% n-octyl-β-D-glucopyranoside (OG1) (Sigma, St. 
Louis, MO, USA), 2mM DTT (Sigma), 2% Biolyte ampholytes pH 3-10 (Bio-Rad, 
Richmond, CA, USA), and 2.5 mM PMSF (Bio-Rad). The cells were removed by 
scraping with a cell scraper (Costar, Cambridge, MA, USA). The insoluble material was 
removed by ultracentrifugation at 35000 rpm at 4 ºC for 1h, and the supernatant was 
stored at -80ºC for further use. 
2.2.2 Chromatofocusing(CF) and Nonporous (NPS) RP-HPLC Separation of 
Ovarian Serous Carcinoma Cell Line Lysates  
 27
CF and NPS RP–HPLC were performed continuously using an integrated protein 
fractionation system ProteomeLab™ PF 2D (Beckman Coulter, Inc. Fullerton, CA, USA). 
An HPCF-1D column (250 × 2.1 mm) was used to perform chromatofocusing. Two 
buffers, a start buffer (SB) (Beckman Coulter, Inc. Fullerton, CA, USA) and an elution 
buffer (EB) (Beckman Coulter, Inc. Fullerton, CA, USA), were used to generate the pH 
gradient on the column. Both buffers were prepared in 6 M urea and 0.2% octyl glucoside. 
Before running the CF, the pH of SB was adjusted to 8.5 +/- 0.1 and EB was adjusted to 
4.0+/- 0.1 using either a saturated solution (50 mg/mL) of iminodiacetic acid (Sigma, part 
# I5629) if the buffer was too basic or 1 M NH4OH if the buffer was too acidic. A PD-10 
G-25 column (Amersham Pharmcia Biotech) was used to exchange the protein sample 
from the lysis buffer to the equilibration buffer used in the CF experiment.  
The HPCF 1D column was first flushed with 100% distilled water (filter through 
a 0.45 um filter) for 10 column volumes at 0.2 mL/min, then equilibrated with 100% SB 
for 30 column volumes. After equilibration with SB, the HPCF column was ready to start 
the ProteomeLab PF 2D default method where injection of the sample began the method. 
After the method had been started, the column was washed with 100% SB to remove 
material that did not bind to the column at pH 8.5. When the wash was complete, the UV 
absorbance returned to baseline. Once a stable baseline was achieved, the method was 
initiated at 100% EB. UV detection was performed at 280 nm and the pH was monitored 
on-line by a flow-through pH probe (Beckman Coulter, Inc. Fullerton, CA, USA). As the 
pH decreased, pH fractions were then collected in 0.15 pH intervals where 30 fractions in 
total were collected in the range of pH 8.5 - 4.0. After the pH of the eluent reached 4.0, 
the HPCF column was washed with 10 column volumes of 1M NaCl and the fractions 
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collected by time. After the salt wash, the HPCF column is washed with 10 column 
volumes of distilled or deionized water. The CF portion of the method for the 
ProteomeLab PF 2D required around 185 minutes.  
When the first-dimension separation was completed, the pI fractions collected 
from the first dimension were then automatically run on the second dimension based on 
the specified ProteomeLab PF 2D sequence. Proteins were resolved by reversed-phase 
chromatography using a HPCF-2D (4.6 × 33 mm) NPS column (Beckman Coulter, Inc. 
Fullerton, CA, USA) and detected by absorbance at 214 nm using a Beckman model 166 
UV absorption detector. Solvent A was 0.1% trifluoroacetic acid (TFA) in water with 
0.05% n-octyl β–D-galactopyranoside and solvent B was 0.08% TFA in acetonitrile with 
0.05% n-octyl β–D-galactopyranoside. The Gradient was run from 15 to 25% B in 1 min, 
25 to 35% in 6 min, 35 to 38% in 4 min, 38 to 45% in 6 min, 45 to 65% in 2 min, 65 to 
67% in 6 min, and finally up to 100% in 1 min, then back to 5% in 1 min. After the 
gradient, the column was washed by two fast gradients from 5% B to 100% B in 5 min, 
100% B back to 5% B in 1 min. At the end of each 2nd-dimension run, the method 
equilibrates the column with an initial mobile phase (A) for 10 column volumes. The 
flow rate used was 0.75 mL/min and the column temperature was 65 ºC. Proteins were 
collected for further analysis using an automated fraction collector. The method 
automatically saves the raw UV absorbance data for each 2nd-dimension analysis of the 
chromatofocusing fractions for protein mapping and data analysis using ProteoVueTM in 
the PF 2D Software Suite. 
2.2.3 MALDI-TOF-MS Sample Preparation and Data Acquisition  
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Before MALDI analysis, each tryptic digested sample was desalted and 
concentrated using C18 ZipTip (Millipore) into 5 µL 60% (v/v) ACN/0.1% (v/v) TFA. 
One microliter of the concentrated peptide mixture was spotted onto a Micromass 96-spot 
plate followed by 1 µL of matrix-standard layered on top of it. The MALDI matrix 
solution was prepared by diluting saturated α-CHCA (Sigma) solution with 60% v/v 
ACN and 0.1% v/v TFA at 1:4 ratio v/v with three internal standard proteins: angiotensin 
I (1296 Da), adrenocorticotropic hormone (ACTH clip 1–17, 2093 Da), and ACTH clip 
18–39 (2465 Da) (Sigma). 1 mg/mL standard proteins were diluted 100-fold with 
deionized water. These standards were further diluted 50, 40, and 30 times, respectively, 
with the diluted matrix. 
The Micromass TofSpec-2E™ (Waters) was used to generate peptide mass 
fingerprints (PMF), followed by database searching in the SwissProt database. Spectra 
were calibrated using the internal calibrants to achieve a mass accuracy of less than 50 
ppm. Monoisotopic peak lists were generated and searched against the SwissProt protein 
database, using the MS-Fit search engine 
(http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm). The search was performed using the 
following parameters: (1) species: human; (2) allowing one missed cleavage; (3) possible 
modifications: peptide N-terminal glutamine to pyroglutamic acid, oxidation of 
methionine, and protein N-terminus acetylated and phosphorylation of S, T and Y; (4) 
peptide mass tolerance 50 ppm; (5) MW ranged from 1000 to 100,000 Da; (6) pI range of 
protein 3–10. Protein identifications were considered confident matches when meeting 
the following criteria: (i) ranked in the top three database hits; (ii) sequence coverage is 
>20%; (iii) average mass error is <50 ppm (iv) MOWSE scores over 104.  
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2.2.4 Electrospray/Ionization TOF-MS 
ESI-TOF-MS analyses of collected protein peak fractions are performed on a 
Micromass LCT™ workstation (Waters, Milford, MA, USA). Ions are generated from a 
z-spray source with a desolvation gas temperature of 150°C at a flow rate of 
approximately 450 L/h. The source is held at 100°C. The capillary voltage is +2800 V, 
the sample cone is +45 V, the extraction cone is +2 V, and the hexapole RF is +750 V 
with a DC offset of +3 V. The second hexapole is biased to -3 V, and the detector is held 
at -2750 V. External calibration is performed by direct infusion of a standard NaI/CsI 
(Sigma) solution. Fractions are infused into the source using a syringe pump (Harvard 
Apparatus, Holliston, MA, USA) at a flow rate of 30–50 µL/min. Data is processed using 
Micromass MassLynx™ v3.4 software (Waters), and protein multiply charged umbrellas 
are deconvoluted using Micromass MaxEnt® 1 software (Waters). Deconvolution 
is performed using a mass range of 5–85 kDa, 1 Da resolution, 0.75 Da peak width, and a 
65% peak height value. 
2.2.5 Software 
  The data from the 2-D liquid separations are displayed using ProteoVue and 
DeltaVue software available in the PF 2D Software Suite (Beckman Coulter, Inc. 
Fullerton, CA, USA). The chromatographic UV intensities result from the NPS HPLC 
second-dimension separation of each pI fraction which were converted and displayed in a 
2-D “lane and band” format by the ProteoVue software resulting in a highly detailed pI 
versus hydrophobicity protein expression map. ProteoVue allows comparison of multiple 
or all second-dimension runs for one sample in a 2-D map using either gray scale or a 
color-coded format where color hue or its intensity is proportional to the relative 
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quantitative UV intensity of each peak. Relationships or patterns within a complex 
chromatographic data set can be easily viewed in this format. The DeltaVue software 
allows side-by-side viewing of the second-dimension runs for two samples or two groups 
of samples so that differences in protein expression between them can be compared. This 
software quantitatively displays one protein map in shades of red and the other map in 
shades of green. The difference between the two maps is obtained by point-by-point 
subtraction or by area difference and displayed as a third map in the middle. The color 
(red or green) at a particular location in the difference map indicates which protein is 
more abundant, and the color brightness indicates the quantitative difference. The 
program also provides a means to obtain a quantitative number between the expression 
levels of protein in the two samples. 
2.2.6 Data analysis and clustering 
2.2.6.1 Data standardization: 
The raw UV data for each sample were standardized to remove differences in the 
level and slope of the baseline.  To do this, for each point, the 10th percentile within a 
window of +/- 50 measurements was calculated and subtracted from the point.  Then 
negative values were replaced with zero, 0.0001 was added to all values, and the data 
were log transformed. 
2.2.6.2 Alignment: 
Standardized UV data for each pair of samples were aligned in order to maximize 
the local correlation coefficients between the aligned samples. Specifically, suppose 
samples A and B are to be aligned.  An alignment is defined by a sequence of index pairs 
(ta(1),tb(1)), (ta(2),tb(2)), ... such that (ta(k+1)-ta(k), tb(k+1)-tb(k)) is equal to (1,0), (1,1), 
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or (0,1).  That is, at each step either the A sequence advances by one index, the B 
sequence advances by one index, or both sequences advance by one index.  At the initial 
point either ta(1) or tb(1) is equal to 1, and at the final point either ta or tb is equal to the 
length of the data sequence (corresponding to the greatest measured hydrophobicity 
value). 
To evaluate alignment quality, for each pair of indices ta in sample A and tb in 
sample B such that |ta - tb| < 150, the correlation coefficient between the data values A(ta-
75)...A(ta+75) and B(tb-75)..B(tb+75) was calculated. The goal is to maximize the sum of 
local correlation coefficients over all possible ta, tb sequences that always remain within 
150 units of each other.  This problem can be efficiently solved using dynamic 
programming techniques. 
2.2.6.3 Comparisons: 
 To compare the overall pattern of protein expression in the samples, each pair was 
aligned separately, as described above, then a correlation matrix was formed by 
calculating the Pearson correlation coefficient between each aligned pair of 
samples.  These correlation matrices were then visualized using a hierarchical clustering 
technique. The hierarchical clustering technique produces a dendrogram in which pairs of 
points are joined sooner (i.e. closer to the ends of the dendrogram) if they have greater 
correlation. Complete linkage clustering was used to define the dendrograms. 
2.2.7 Biomarker Identification: 
 To identify potential biomarkers, all samples were first aligned to a single sample 
selected as the standard.  Then comparisons were made separately at each hydrophobicity 
level between two groups of samples.  Values were selected if the ratio between mean 
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levels within the two groups exceeded 4, and if the t-test p-value between the two groups 
was less than 0.05.  In addition, at least 25 consecutive hydrophobicity levels were 
required to meet these conditions in order for the band to be considered as a biomarker. 
2.3 Results and Discussion  
2.3.1 Cell lines 
Eight ovarian serous carcinoma-derived cell lines and three OSE cell lines (IOSE-
144, IOSE-80 and HOSE-A) were used to study ovarian cancer proteomes (Table 1). 
HOC-1 was derived from ascites tumors of a patient with well-differentiated serous 
adenocarcinoma of the ovary (19). HEY was established from a moderately differentiated 
papillary (serous) cystadenocarcinoma of the ovary, which had been passaged previously 
as a xenograft in immunocompromised mice (19). PEO1 was derived from the ascites of 
a patient with poorly differentiated serous adenocarcinoma after treatment by 
chemotherapy (20). Both HEY and PEO1 produce tumors in immunocompromised mice 
(19, 20), whereas HOC-1 does not. The ovarian carcinoma cell lines DOV13, OVCA420, 
OVCA429, OVCA432, and OVCA433 were originated from serous cystadenocarcinoma 
(21). 
The clear cell carcinoma line ES-2 and two endometrioid carcinoma cell lines 
MDAH-2774 and TOV-112D were also mapped by the 2-D liquid method for 
comparison to the serous carcinoma cell lines. ES-2 was established from a surgical 
tumor specimen described as a poorly differentiated ovarian clear cell carcinoma. Tumors 
develop when nude mice are inoculated subcutaneously (22). The MDAH-2774 cell line 
was developed from cells in the ascites fluid from a patient with endometrioid ovarian 
cancer and forms tumors in nude mice (23). TOV-112D was derived from an 
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endometrioid carcinoma from a patient who were never exposed to chemotherapy or 
radiation therapy (24). 
Three MCF10 breast epithelial cell lines [MCF10AT1, MCF10CA1a.cl1 (CA1a) 
and MCF10CA1d.cl1 (CA1d)] were also mapped and compared to the ovarian carcinoma 
cell lines. The MCF10A cell line originated from a patient with fibrocystic disease (25). 
MCF10AT1 cells are MCF10A cells transformed with a mutant c-Ha-ras protein (T24). 
This line forms preneoplastic lesions in nude mice that represent a premalignant stage 
with potential for neoplastic progression. CA1a and CA1d were derived from xenografts 
of MCF10AT1. When subcultured and re-xenografted, these lines rapidly form invasive 
carcinomas with metastatic potential and display histologic variations ranging from 
undifferentiated carcinomas to well-differentiated adenocarcinomas (26). 
2.3.2 Analysis of ovarian cancer proteomes 
The primary objective of this study was to classify large numbers of samples by 
mapping and comparing 2D liquid maps generated with UV detection so that we can 
obtain basic information on the similarities and differences among ovarian cancer cell 
lines. OSE and serous carcinoma-derived cell lines were fractionated using 
chromatofocusing at 0.15 pI intervals. Each of these fractions was automatically collected 
and continuously injected into the second dimension column using nonporous silica (NPS) 
RP-HPLC. The result is a virtual 2-D UV map profile, which displays the pI versus 
hydrophobicity of the protein expression for the whole cell lysate. Protein detection in the 
first dimension step is performed using UV absorption at 280 nm and 214 nm in the 
second dimension. As an example, the profile of serous carcinoma HOC-1 is shown in 
Figure 1. In Figure 1, ~4.0 mg or 2.0 ×107 cells were loaded onto the first dimension 
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chromatofocusing column. In this figure, each lane corresponds to a different pI value 
and the bands correspond to the hydrophobicity as generated by the % acetonitrile on the 
HPLC gradient at that pI. For each map, a total of 28 pI fractions have been mapped 
which correspond to a pH range of 4.11 – 8.32. The more acidic and basic fractions are 
not shown here because few proteins were detected. Many of the RP-HPLC fractions 
obtained after chromatofocusing contained as many as 60-100 proteins. As a 
representative example the different proteins separated by NPS RP-HPLC from the pI 
fraction 4.85 -5.00 of sample DOV13 are shown in Fig. 2. It is estimated that each sample 
was fractionated into over 1500 protein bands using the 2-D liquid mapping method.  
In each of the samples used to generate the 2-D UV map, the protein content was 
determined by the Bio-Rad protein assay. Equal amounts of protein were loaded onto the 
first dimension chromatofocusing column so that a quantitative comparison could be 
obtained. The UV patterns of ovarian cancer proteins were highly reproducible within 
each cell line. The CF reproducibility is shown in Figure 3a, where sample IOSE-144 was 
run by CF three separate times. In each case different amounts of sample were loaded 
onto the CF column, 3.5mg, 4.0mg and 4.5mg respectively. The second dimension 
hydrophobicity profiles reproducibility is highlighted for one of the pI lanes from the 
total expression profile and is shown in Figure 3b. These results show that the 
chromatogram of the band patterns and retention times in both the first dimension 
chromatofocusing separation and the second dimension reverse phase liquid separation 
are very similar. This was found to be the case in all the pI lanes separated for all samples 
(data not shown). The 2-D liquid mapping protocol allows the production of highly 
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reproducible differential maps where hundreds of proteins can be compared by computer 
analysis for a large number of samples. 
The digitized protein profile that results from our liquid separation is relatively 
reproducible from run to run for the same sample. Reproducible 2-D liquid separations 
with well resolved protein peaks are a prerequisite for the establishment of a reference 
map of the proteome of the ovarian serous carcinoma cell lines for interlysate 
comparisons. The overall resolution and reproducibility pattern of the 2D separation was 
greatly improved by the automated system. This reproducibility makes it possible to 
compare different cell lines for large numbers of samples, which is essential for searching 
for biomarkers.  
The peak patterns for each pI fraction of each cell line were aligned using a 
dynamic programming technique. The samples were transformed for reasonable 
statistical analysis.  The transform first subtracts the baseline of the curve so that a flat 
baseline at zero was obtained; next, each point was taken as the natural log.  A difference 
of 1 unit on the y-axis corresponds to a roughly 2.7 fold difference in the UV readout. 
Two original data sets of sample HEY and PEO1, fraction pH 4.55-4.70, gradient range 
from 41.5% to 49.5% are shown in Figure 4a. The index of data pairs aligned together is 
used as x-axis units and the converted intensity of each peak as we described above is 
used as y axis units. The data sets that were aligned using this method are shown in 
Figure 4b. It is seen that the two traces are not well aligned originally, but after stretching 
of the profile, the alignment is much improved. The chromatographic profiles are 
properly aligned to compensate for minor drifts in retention times. These small retention 
time shifts may be due to changes in the columns during use, minor changes in mobile 
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phase composition, drift in the instrument, interaction between analytes, etc. This 
alignment technique compensates for these drifts and allows comparisons of protein 
bands in different cell lines for large numbers of samples. 
In order to compare the overall pattern of protein expression in the samples, after 
each pair was aligned separately, a correlation matrix was formed by calculating the 
Pearson correlation coefficient between each aligned pair of samples.  These correlation 
matrices were then visualized using hierarchical clustering techniques.  Here we used 
three different cluster analyses, "single linkage", "complete linkage", and "average 
linkage" hierarchical clustering (27). Differences between these three methods arise 
because of the different ways of defining distance (or similarity) between clusters. Single 
linkage is also known as the nearest neighbor technique where the distance between 
groups is defined as the distance between the closest pair of objects and only pairs 
consisting of one object from each group are considered. The complete linkage involves 
the farthest neighbor, where the clustering method is the opposite of single linkage--
distance between groups is defined as the distance between the most distant pair of 
objects, one from each group. For average linkage, the distance between two clusters is 
defined as the average of distances between all pairs of objects, where each pair is made 
up of one object from each group. All the fractions, from pH 8.32 to pH 4.11, were 
analyzed by these three different methods. Total results are obtained by the average of all 
the fractions and are shown in Figure 5a, 5b and 5c.  In the dendrograms, the length and 
the subdivision of the branches display the relatedness of the cell lines and the expression 
of the proteins.  
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The dendrograms in figure 5 shows the relationship of the different serous 
carcinoma cell lines based upon their protein expression using the 2-D liquid mapping 
technique. In order to evaluate the method, we analyzed two sets of samples as IOSE-
144-1 and IOSE-144-2. It was found that using these three different clustering methods, 
OSE cell lines IOSE-144 and HOSE-A clustered together (Figure 5), while the two 
IOSE-144 samples clustered together most closely as expected. In addition, several 
serous carcinoma cell lines clustered with each other, i.e., DOV13, OVCA429, and 
OVCA433 clustered together. It is interesting that IOSE-80, which was derived from 
OSE, clusters with serous carcinoma lines HEY and PEO1. Indeed, IOSE-80 appears to 
be strongly linked to PEO1 throughout the pI fractions of the 2-D maps. This is not 
surprising since the IOSE-80 cell line has been cultured for many passages and may have 
obtained some of the characteristics of the carcinoma-derived lines. Although limited 
information is available on the cell lines, it is shown that the protein expression of certain 
cell lines is closely related to others and that these cluster together on the dendrogram. In 
order to show the relationship between some of these cell lines that cluster together, the 
corresponding protein expression maps for a given pH fraction are shown in Figure 6. In 
the fractions that cluster together a number of protein bands are common to the different 
cell lines that define this relationship.  
In addition to the serous carcinoma cell lines, several other ovarian and breast 
tumor cell lines were mapped by the 2-D liquid method. It is interesting to note that ES-2, 
MDAH-2774 and TOV-112D cluster closely together. This is not unexpected given the 
detailed 2-D mapping of proteins in previous work (17, 28) where the ES-2 clear cell line 
and MDAH-2774 were found to have many bands in common between them and in more 
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recent work (29) where TOV-112D was found to be somewhat similar also. Other 
interesting clusters include those from the MCF10 breast epithelial cell lines. Ca1d and 
Ca1a are related highly malignant breast cancer lines derived from xenografts of AT1 and 
cluster together as expected. In addition, AT1, which is a premalignant breast epithelial 
cell line also derived from MCF10, clusters closely with the other breast cancer cell lines 
as expected.  
In order to quantify differences between the immortalized OSE lines (IOSE-144, 
HOSE-A), ovarian carcinoma-derived lines (ES-2, MDAH-2774, TOV-112D), and breast 
epithelial (AT1, Ca1a, Ca1d) cell line groups, the pair-wise correlation coefficients were 
calculated using normalized data between 24 pI ranges which were aligned separately for 
each pair of samples and the Pearson correlation coefficients were calculated between the 
resulting aligned values. These were averaged for all distinct sample pairs within each of 
these three groups to produce a single within-group correlation coefficient for each 
group.  Similarly, for every pair among these groups, correlation coefficients for every 
pair of samples spanning the two groups were averaged to produce a single between-
group average correlation coefficient.  These within-group and between-group correlation 
coefficients were prepared separately for each fraction, and also averaged across the 
fractions to provide an overall summary. It is interesting that the actual correlation 
numbers are such that correlation between the breast and ovarian clusters is greater than 
that of the ovarian carcinoma and OSE clusters, which in turn is greater than that of the 
breast and OSE clusters as represented in the dendrograms. It would be expected that the 
breast cancer and OSE clusters would have the lowest correlation. 
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There is some information on the molecular relationship of these cell lines based 
upon gene expression profiles in prior work (4, 30). There are some similarities in terms 
of the cell lines that cluster together compared to the protein mapping, but also very 
distinct differences. ISOE-144, IOSE-80 and HOSE-A cluster together by gene 
expression, but IOSE-80 distinctly does not cluster with these lines in the protein maps. 
Based on the mRNA expression data, ES-2 clear cell line clusters with the OSE samples 
while MDAH-2774 does not cluster with ES-2 or TOV-112D, but rather with the serous 
carcinoma cell lines. TOV-112D appears to cluster by itself in the gene expression arrays, 
whereas in the protein maps it clearly clusters with MDAH-2774 and ES-2. HEY and ES-
2 were found to cluster in the gene expression data (4, 30), but HEY clustered with PEO1 
in the protein expression data which makes sense since these are both serous carcinomas. 
OVCA429 and OVCA433 are closely clustered by gene expression as in the case of the 
protein mapping and OVCA432 is reasonably closely linked in both cases. OVCA420 is 
not closely linked to the OSE cell lines as in the protein expression maps. Nevertheless, it 
is not surprising that the gene expression and protein expression clusters provide different 
information since in prior work (28) it was found that the gene expression and protein 
expression for several cell lines had a poor correlation. Such poor correlation has been 
observed in other studies (31) and is due to the fact that many of the mRNA messages do 
not translate into proteins (32) or the proteins produced are short-lived or misfolded and 
rapidly degraded (33). Ultimately, though, it is the protein expression that determines the 
function of the cell so that the relationships as determined by protein mapping will be 
essential for searching for distinctive markers of cancer. 
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An important capability of the 2-D mapping technique is the use of proteomic 
patterns for classification using common marker bands in the comparison of different 
clusters of cell lines. The peak retention time and intensity for each band can be obtained 
using the Beckman software. As an example the average number of peaks for 11 samples 
for fraction pI 7.57-7.72 is 67. Based on the protein expression map, proteins can be 
classified into three groups. One group of proteins is likely to be common to most cell 
types. For this fraction, we found 12 proteins of all cells have the same retention time and 
are likely to be the same. A second set of proteins appears to be linked to one group of 
cell lines only. This set may provide the basis for detection and classification of serous 
carcinoma and have the potential to provide identifying biomarkers. A third group of 
proteins appears to be expressed uniquely on each individual cell line. It is possible to 
hypothesize that this third group of proteins is responsible for unique aspects of cell 
behavior.  
In order to identify markers of groups of serous carcinoma cell lines, 
standardization and alignment of bands were performed and then comparisons were made 
separately at each hydrophobicity level between two groups of samples. A differentially 
expressed band is selected on the basis of having at least 4-fold different mean level 
within the two groups of samples. In addition, at least 25 consecutive hydrophobicity 
levels were required to meet these conditions in order for the band to be considered as a 
marker. Figure 7 shows peak patterns for two cluster samples, one group as OVCA429, 
OVCA433, and DOV13 and the other group as IOSE-80, PEO1, and HEY. The image is 
displayed in a format with each different sample on the x-axis and hydrophobicity on the 
y-axis. The relative intensities of the band are quantitatively proportional to the amount 
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of corresponding protein detected by UV absorption. The three groups of bands are only 
observed in the group IOSE-80, PEO1, and HEY but not in the group of OVCA433, 
OVCA429, and DOV13. After the identification with MALDI-TOF mass spectrometry 
combined with ESI-TOF-MS, we got the protein IDs are Dickkopf related protein-1 
precursor, Histone H2B and NACHT, LRR and PYD-containing protein 10. Figure 8 
shows the total ion chromatogram of LCT with three small windows showing three 
spectrum of MALDI for each peak which corresponds to a single spot in Figure 7. Table 
2 shows the detail information about identify these three proteins. The use of differential 
analysis allows us to identify proteins that may be common bands for classification and 
limits the number of proteins that might require further analysis by mass spectrometric 
techniques.  
2.4 Conclusion 
The use of the 2-D liquid mapping serves as a powerful tool for comparing the 
protein expression profiles of large numbers of samples. It provides an automated method 
for reproducibly running samples for interlysate comparisons. This strategy provides a 
means for comparing the profiles of different samples and classifying them according to 
the protein bands observed in their expression maps. This method has been used to 
classify a number of serous carcinoma cell lines compared to OSE lines and also several 
ovarian clear cell and endometrioid and breast epithelial cell lines. The results show that 
in most cases the serous carcinoma clustered within several groups while the breast 
cancer and other ovarian cell lines clustered separately. The method provides a means to 
search for markers that may serve to classify a specific set of cancers. It also reduces the 
potentially large amounts of protein expression data from a large number of samples into 
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a manageable data set. It thus reduces the number of significant bands that need to be 





















Cell Line Description 
          HOSE-A HPV16 E6/E7 immortalized ovarian surface epithelium (OSE) 
          IOSE-144  Life-extended (with SV-40 large T antigen) OSE cell lines 
          IOSE-80 Life-extended (with SV-40 large T antigen) OSE cell lines 
          HOC1  Ovarian serous carcinoma 
          PEO1 Ovarian serous carcinoma  
          DOV13 Ovarian serous carcinoma 
          HEY Ovarian serous carcinoma 
          OVCA420 Ovarian serous carcinoma 
          OVCA429 Ovarian serous carcinoma 
          OVCA432 Ovarian serous carcinoma 
          OVCA433 Ovarian serous carcinoma 
          ES-2 Ovarian clear cell adenocarcinoma 
          MDAH-2774 Ovarian endometrioid adenocarcinoma 
          TOV-112D Ovarian endometrioid adenocarcinoma 
          CAld Fully malignant human breast cancer cells  
          Ca1a Fully malignant human breast cancer cells 








Table 2.2 Proteins identified for differentially expressed spots. 





















Figure 2.1 A blow-up of a portion of the 2-D liquid protein expression map of the 
ovarian cancer serous cell line HOC-1 whole cell lysate. Ovarian cancer serous cell line 
HOC-1 was separated using chromatofocusing over a pH range of 4.11 – 8.32 with 0.15 
pH interval followed by separation in the second dimension using NPS RP-HPLC. The x-
axis is pI of the chromatofocusing and the y-axis is hydrophobicity of the RP-HPLC. The 











































 2      3      4     5      6      7      8     9     10   11    12    13   14    15    16  
 47




















Figure 2.2 NPS RP-HPLC separation of one CF fraction Ovarian cancer serous cell line 
























Figure 2.3 Reproducibility study of 2-D liquid separation. A. Chromatofocusing has been 
run three separate times on IOSE-144 sample, totally amount of sample was 3.5mg, 
4.0mg and 4.5mg, where the protein content of the IOSE-144 cell lines is detected by UV 
absorption at 280nm. B. 2nd dimension has been run continuously by NPS RP-HPLC for 






































Figure 2.4. Alignment analysis. Superimposed sections of the chromatographic trace at 
214nm from NPS RP-HPLC analysis of two serous samples, HEY and PEO1 fraction pI 
4.55-4.70, gradient range from 41.5% to 49.5%. A.Prior to aligning  B. After stretching 

























































Figure 2.5 Hierarchical clustering analysis. Cell lines are aligned separately and grouped 
based on similarities in their protein expression using a hierarchical clustering analysis 
technique. This technique produces a dendrogram in which pairs of points are joined 
sooner (i.e. closer to the ends of the dendrogram) if they have greater correlation. A. 


















































Figure 2.6 Protein expression maps for a given pH fraction. Fraction pI 4.55-4.70, 
gradient ranges from 30.0% to 78.0%. The relative intensities of the bands are 



































Figure 2.7 Differential analysis. Fraction pI 7.57-7.72, gradient ranges from 30.8% to 
67.0%. The relative intensities of the bands are quantitatively proportional to the amount 
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Mass Mapping Study for Ovarian Serous Carcinoma Cell Lines 
 
3.1 Introduction 
Ovarian cancer is the most lethal gynecologic tumor in the United States and in 
the Western world. Based on morphological criteria, there are four major histological 
types of primary ovarian carcinomas (serous, clear cell, endometrioid, and 
mucinous).Among all these histological subtypes of ovarian cancer, serous carcinoma is 
the most common one and accounting for nearly 50% of all ovarian epithelial tumors (1). 
Most ovarian epithelial tumors are believed to be derived from the ovarian surface 
epithelium (OSE) (2, 3) and consist of benign, low malignant epithelial tumors, and 
invasive carcinomas (4, 5). Although surgery followed by chemotherapy is able to induce 
clinical responses in the majority of ovarian cancer patients, most of these women 
eventually die from the development of chemotherapy-resistant disease (1). It is very 
important for the identification of novel molecular markers which is useful for the early 
diagnosis and therapy of ovarian cancer patients. A better understanding of the molecular 
expression in normal ovarian samples and in ovarian cancer will likely provide promising 
targets for novel therapeutic strategies. 
In order to identify markers with a differential pattern of expression between 
ovarian tumors and normal ovarian cells and to use this knowledge for the development 
of novel diagnostic and therapeutic markers against this disease, many studies have been 
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applied to compare the expression profiles of ovarian cancer to those of normal ovaries 
(6-9). Although cancer can be described as a disease of genes, mRNA and protein 
expression from a given gene may be discordant and it is the protein products of genes 
that actually determines the function and structure of the cells. The use of protein 
expression may be more informative and could lead to biologic insights and potential 
improvements in diagnosis and treatments for this disease. LC-MS based multi-
dimensional separation methods are rapidly emerging. This technique can apply large 
scale protein expression profiling analysis and identify the relative quantities of the 
various proteins between different samples (10-13). Our group has developed a 2-D 
liquid phase mass mapping method which can explore protein-based expression profiling 
for ovarian cancer classification and to search for subtype-specific biomarker candidates 
(14). The method involved fractionation according to pI using chromatofocusing in the 
first dimension followed by separation of the proteins in each pI fraction using nonporous 
RP HPLC, which was coupled to an ESI-TOF mass analyzer for molecular weight (MW) 
analysis. A 2-D mass map of the protein content of each ovarian cancer samples based 
upon pI versus intact protein MW was generated. 
 In the present work, we demonstrate the capabilities of using the 2-D liquid phase 
separation of protein method combined with on-line ESI-TOF mass spectrometry for 
mapping five ovarian serous carcinoma cell lines and one epithelial cell line IOSE-80. It 
is shown that using this method, we have mapped several interesting pI fractions and 
have plotted them as a 2-D map of pI versus accurate MW. Some interesting proteins 
have been collected in the liquid phase and analyzed by MALDI-TOF mass spectrometry, 
where their confident ID can be obtained by combing both intact molecular weight and 
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peptide fingerprint. The comparison can be made quantitative by the use of internal 
standards to normalize for the changes in ESI intensity. Clustering can be applied to those 
cell lines based on their mass map and a comparison can be made between different 
groups based on the clustering results.  
3.2 Experimental Section 
3.2.1 Cell Culture and Sample Preparation  
A total of six ovarian cell lines were applied in this study, which included five 
serous and one immortalized ovarian surface epithelial cell line. Ovarian serous 
carcinoma-derived cell lines HEY were a gift from L. Dubeau (USC School of Medicine, 
Los Angeles, CA); DOV13, OVCA429 and OVCA433 were a gift of D. Fishman (North-
western University, Chicago, IL); PEO1 was a gift from T. Hamilton (Fox Chase Cancer 
center, Philadelphia, PA). Ovarian surface epithelial cells expressing SV40 large T 
Antigen (IOSE-80) were a gift of N.Auersperg (University of British Columbia, 
Vancouver, British Columbia, Canada). Cells were cultured as previously described  (15). 
All the cell lines were cultured under standard conditions in the Department of Pathology 
at the University of Michigan Medical School. The cells were maintained in DMEM/10% 
fetal bovine serum and 1% Penicillin/Streptomycin (Invitrogen, Gaithersburg, MD).  
When monolayer cultures were 80-90% confluent, the cells were washed three times with 
phosphate buffered saline (PBS) and lysed in lysis buffer. Lysis buffer (90 µL/cm2) 
consisted of 6 M urea (INC Biochemicals, Cleveland, OH, USA), 2M thiourea (INC), 1% 
n-octyl-β-D-glucopyranoside (OG1) (Sigma, St. Louis, MO, USA), 2mM DTT (Sigma), 
2% Biolyte ampholytes pH 3-10 (Bio-Rad, Richmond, CA, USA), and 2.5 mM PMSF 
(Bio-Rad). The cells were removed by scraping with a cell scraper (Costar, Cambridge, 
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MA, USA). The insoluble material was removed by ultracentrifugation at 35000 rpm at 4 
ºC for 1h, and the supernatant was stored at -80ºC for further use. 
3.2.2 Chromatofocusing(CF)  
CF was performed using ProteomeLab™ PF 2D system (Beckman Coulter, Inc. 
Fullerton, CA, USA). An HPCF-1D column (250 × 2.1 mm) was used to perform 
chromatofocusing. Two buffers, a start buffer (SB) (Beckman Coulter, Inc. Fullerton, CA, 
USA) and an elution buffer (EB) (Beckman Coulter, Inc. Fullerton, CA, USA), were used 
to generate the pH gradient on the column. Both buffers were prepared in 6 M urea and 
0.2% octyl glucoside. Before running the CF, the pH of SB was adjusted to 8.5 +/- 0.1 
and EB was adjusted to 4.0+/- 0.1 using either a saturated solution (50 mg/mL) of 
iminodiacetic acid (Sigma, part # I5629) if the buffer was too basic or 1 M NH4OH if the 
buffer was too acidic. A PD-10 G-25 column (Amersham Pharmcia Biotech) was used to 
exchange the protein sample from the lysis buffer to the equilibration buffer used in the 
CF experiment.  
The HPCF 1D column was first flushed with 100% distilled water (filter through 
a 0.45 um filter) for 10 column volumes at 0.2 mL/min, then equilibrated with 100% SB 
for 30 column volumes. After equilibration with SB, the HPCF column was ready to start 
the ProteomeLab PF 2D default method where injection of the sample began the method. 
After the method had been started, the column was washed with 100% SB to remove 
material that did not bind to the column at pH 8.5. When the wash was complete, the UV 
absorbance returned to baseline. Once a stable baseline was achieved, the method was 
initiated at 100% EB. UV detection was performed at 280 nm and the pH was monitored 
on-line by a flow-through pH probe (Beckman Coulter, Inc. Fullerton, CA, USA). As the 
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pH decreased, pH fractions were then collected in 0.15 pH intervals where 30 fractions in 
total were collected in the range of pH 8.5 - 4.0. After the pH of the eluent reached 4.0, 
the HPCF column was washed with 10 column volumes of 1M NaCl and the fractions 
collected by time. After the salt wash, the HPCF column is washed with 10 column 
volumes of distilled or deionized water. The CF portion of the method for the 
ProteomeLab PF 2D required around 185 minutes.  
3.2.3 LC/ESI-TOF-MS 
 
When the first-dimension separation was completed, the pI fractions collected 
from the first dimension were then run on the second dimension. Proteins were resolved 
by reversed-phase chromatography using a HPCF-2D (4.6 × 33 mm) NPS column 
(Beckman Coulter, Inc. Fullerton, CA, USA). The LC separation was performed at a flow 
rate of 0.4 mL/min and the column temperature was 65 ºC.. Solvent A was 0.1% TFA 
and 0.3% formic acid (FA) in H2O and solvent B was 0.08% TFA and 0.3% formic acid 
(FA) in. The Gradient was run from 15 to 25% B in 1 min, 25 to 35% in 6 min, 35 to 
38% in 4 min, 38 to 45% in 6 min, 45 to 65% in 2 min, 65 to 67% in 6 min, and finally 
up to 100% in 1 min, then back to 5% in 1 min. The column was equilibrated with 5% of 
solvent B until the A of UV (214 nm) (Thermo separation products sp UV 200, FL) 
became stable and the protein fraction from CF separation was applied to the column. A 
postcolumn splitter was used to split the effluent into half. Half of the effluent was 
delivered into the source of Micromass LCT™ workstation (Waters, Milford, MA, USA). 
The other half of the effluent was passed through a Beckman model 166 UV absorption 
detector (214 nm) and collected using a Beckman SC-100 fraction collector for MALDI-
TOF MS analysis. The LCT parameters were set as follows: desolvation temperature 
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300ºC, source temperature 110ºC, desolvation gas 970 L/h, capillary voltage 13200 V, 
sample cone 135 V, extraction cone 12 V, and rf voltage 750 V. Before sample injection, 
the external calibration was utilized with the direct infusion of NaI-CsI solution by a 
syringe pump. Bovine insulin (0.25 ug) was mixed with samples and injected into the 
LC-MS for calibration and quantification. Maxent1 software was used for LCT data 
analysis. The total ion chromatogram (TIC) was scanned for regions that contain 
redundant multiple-charged peaks, and those regions were combined for deconvolution. 
The deconvoluted peaks were subsequently combined into a single mass spectrum, which 
was converted to a text file for input into the 2-D mapping software (Proteovue) written 
in-house. Data is processed using Micromass MassLynx™ v3.4 software (Waters), and 
protein multiply-charged umbrellas are deconvoluted using Micromass MaxEnt® 1 
software (Waters). Deconvolution is performed using a mass range of 5–85 kDa, 1 Da 
resolution, 0.75 Da peak widths, and a 65% peak height value. 
3.2.4 Tryptic digestion of the LCT fractions  
Fractions collected from the LCT separation were concentrated down to 20 mL 
using a Speedvac concentrator (Labconco, Kansas City, MO). To the reduced volume 
fractions,10% v/v 10 mM DTT (Sigma), 10 mL 1M NH4 HCO3(Sigma) and 0.25 mg of 
TPCK-treated trypsin (Promega, Madison, WI) were added. The fractions were then 
incubated at 37ºC for 24 h. After 24-h incubation, 1 ul TFA was added into each fraction 
to stop digestion.  
3.2.5 MALDI-TOF-MS Sample Preparation and Data Acquisition  
Before MALDI analysis, each tryptic digested sample was desalted and 
concentrated using C18 ZipTip (Millipore) into 5 µL 60% (v/v) ACN/0.1% (v/v) TFA. 
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One microliter of the concentrated peptide mixture was spotted onto a Micromass 96-spot 
plate followed by 1 µL of matrix-standard layered on top of it. The MALDI matrix 
solution was prepared by diluting saturated α-CHCA (Sigma) solution with 60% v/v 
ACN and 0.1% v/v TFA at 1:4 ratio v/v with three internal standard proteins: angiotensin 
I (1296 Da), adrenocorticotropic hormone (ACTH clip 1–17, 2093 Da), and ACTH clip 
18–39 (2465 Da) (Sigma). 1 mg/mL standard proteins were diluted 100-fold with 
deionized water. These standards were further diluted 50, 40, and 30 times, respectively, 
with the diluted matrix. 
The Micromass TofSpec-2E™ (Waters) was used to generate peptide mass 
fingerprints (PMF), followed by database searching in the SwissProt database. Spectra 
were calibrated using the internal calibrants to achieve a mass accuracy of less than 50 
ppm. Monoisotopic peak lists were generated and searched against the SwissProt protein 
database, using the MS-Fit search engine 
(http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm). The search was performed using the 
following parameters: (1) species: human; (2) allowing one missed cleavage; (3) possible 
modifications: peptide N-terminal glutamine to pyroglutamic acid, oxidation of 
methionine, and protein N-terminus acetylated and phosphorylation of S, T and Y; (4) 
peptide mass tolerance 50 ppm; (5) MW ranged from 1000 to 100,000 Da; (6) pI range of 
protein 3–10. Protein identifications were considered confident matches when meeting 
the following criteria: (i) ranked in the top three database hits; (ii) sequence coverage is 
>20%; (iii) average mass error is <50 ppm (iv) MOWSE scores over 104.  
3.2.6 Clustering analysis 
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Protein abundances for each sample were first log (base 2) transformed and 
summed with consecutive, non-overlapping windows of width 26104 PPM. That is, 
starting at a lower mass bound of 5000 Da, the first window spanned from 5000 to 
5000(1 1 26104/106) Da = 5100 Da, the second window spanned from 5100 Da to 
5100(1 1 26104/106) Da = 5202 Da, and so on. At a typical protein mass of 50 kDa, the 
mass window was 1000 Da wide, with wider windows at greater masses and narrower 
windows at lesser masses. Absolute measurement error is greater for larger proteins, and 
larger proteins are presumed to have greater mass variation due to PTMs. Based on the 
mass maps, clustering can be applied according to the clustering analysis using in-house 
software Pathon. Next, two-sample t-tests were performed within each window, to 
compare the mean expression level in one group from the mean expression level in the 
other group. A significant difference was defined when the t-test pvalue was less than 
0.01 and when the levels within each group had standard deviation greater than 1026. For 
display purposes , bands with significantly greater expression in one group were colored 
pink and bands with significantly greater expression for another gorup were colored cyan. 
Bands in which a nonzero abundance was detected in every sample were colored yellow. 
3.3 Results and Discussion 
3.3.1 Cell lines 
Five ovarian serous carcinoma-derived cell lines and one OSE cell lines IOSE-80 
were used to study ovarian cancer proteomes. Their description was shown on Table 1.  
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3.3.2 Analysis of ovarian cancer proteomes 
A 2-D liquid phase mass mapping method has been developed in our laboratory 
and applied to profile protein expression in ovarian serous cancer cell lines. Proteins 
extracted ovarian carcinoma samples were separated by utilizing this 2-D liquid phase 
separation method and detected intact molecular weight in order to do the classification 
and comparison based on their protein expression. This analytical approach fractionated 
proteins by CF in the first dimension based on pI, and each pH fraction was further 
separated by nonporous (NPS)-RP-HPLC in the second dimension. The protein eluents 
from NPS-RP-HPLC were interfaced online to ESI-TOF to obtain an accurate and 
reproducible protein intact molecular weight. The 2-D mass maps of each sample were 
finally generated by the Proteovue or Deltavue software, which also allows for highly 
accurate protein profile comparisons between the two different groups of ovarian cancer.  
Figure 1 shows a representative chromatograph we obtained using the LCT as a 
detector. In each injection, we inject 0.25ug insulin as an internal standard. We can thus 
normalize the data to compensate the small variance due to different instrumental 
conditions. In this figure, we indicate a small peak with retention time 10.602. Compared 
to the insulin peak, it is quite small; however, after mass combination and deconvolution, 
we can still obtain a good molecular weight value and which shows the excellent 
sensitivity of this method.  
Figure 2 shows the 2-D comparison mass map of 4 serous ovarian cancer samples 
generated from a selected pH fraction (5.15–5.30). The horizontal and vertical 
dimensions of the 2-D protein content map are plotted in terms of the selected pI range 
and protein intact MW, respectively. Each vertical lane on the map represents the protein 
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content of the same selected pH fraction collected from each sample. Each band 
represents a protein eluted from RP-HPLC and detected by ESI-TOF. From the mass 
expression, we observe that there are differences and similarities between these four 
samples. Some proteins are the same for all four samples and some are unique for each 
sample. As mentioned in the methods, a postcolumn splitter was used to split the effluent 
after HPLC separation. Half of the effluent was delivered into the source of the 
Micromass LCT™ workstation and the other half of the effluent was passed through a 
UV detector and collected for MALDI-TOF MS analysis.  Combining the information 
from mass spectrometry, we can obtain a confident ID based on the intact molecular 
weight and peptide fingerprint. Table 2 shows the protein identified from Peo1 fraction pI 
5.15-5.30. We also studied the similarities between these four serous cell lines. Table 3 
shows the common proteins identified for these four samples. The LCT intact molecular 
weight is listed for each sample. Most of these proteins have the same intact molecular 
weight for four samples which means this method is very reproducible. The small 
variance may due to the small shift of the calibration. Figure 3 shows the comparisons of 
four serous carcinoma samples’ intact protein molecular weight obtained by electrospray 
TOF-MS fraction pI 4.40-4.55, pI 4.85-5.00 and pI 5.00-5.15. These 2-D maps provide 
an overview of protein mass distribution and composition in each fraction. 
An important capability of the 2-D mapping technique is the use of proteomic 
patterns for comparison to find those differentially expressed proteins which may serve as 
potential makers. In Figure 4, the IOSE80 cell line is displayed with the protein bands in 
shades of red, while the OVCA429 cell line is displayed with the protein bands in shades 
of green. The lane in the center is the differential display where the intensities of the 
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protein bands of the same MW have been subtracted from one another. There are some 
proteins which are highly expressed in the normal cell line while some proteins are highly 
expressed in cancer cell lines. After identification using both intact molecular weight and 
peptide fingerprint, we marked the differentially expressed proteins in the figure. 
3.3.3 Hierarchical clustering analysis 
 
The hierarchical clustering method was used for classification on six ovarian cell 
lines based on their similarities in protein expression. This technique produces a 
dendrogram in which pairs of points are joined sooner (i.e. closer to the ends of the 
dendrogram) if they have greater correlation. In-house software Pathon was used to do 
the classification. Three different cluster analyses: “single linkage,” “complete linkage,” 
and “average linkage” hierarchical clustering were used. Differences between these three 
methods arise because of the different ways of defining distance (or similarity) between 
clusters. Two different fractions were applied in Figure 5. From the results we observed 
that some specific cell lines are grouped together. 
3.4 Comparison of expression patterns distinguishes different groups 
The comparison between two different groups can be viewed using the mass 
mapping technique.  As in Figure 6, group OVCA432, OVCA429 and DOV13 were 
compared with group HEY, PEO1 and IOSE80. For identification of differentially 
expressed proteins between the two different groups, the protein mass range was divided 
into windows of 20 000 PPM widths; that is, a window that starts at K Daltons ends at K 
1 K/20 Daltons. This window was chosen to include possible isoforms due to 
posttranslational modifications. Other windows of 10 000 PPM and 5000 PPM were also 
tested and, generally, similar results were obtained(data not shown). A non-overlapping 
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sequence of windows was constructed covering the entire measured range. Within each 
of these windows, the total measured protein amount was summed for each sample, and 
these sums were compared between the samples using two-sample t-tests. Figure 6 shows 
the results of this analysis for two selected pI range. Pink bands in the figure correspond 
to mass ranges that are significantly more abundant in group OVCA432, OVCA429 and 
DOV13. Blue bands correspond to mass ranges that are significantly more abundant in 
group HEY, PEO1 and IOSE80. Yellow bands correspond to mass ranges in which all 
samples have some level of measured protein expression. 
3.4 Concluding Remarks 
 
A 2-D liquid phase mass mapping method has been applied to explore variations 
in protein expression related to ovarian serous carcinoma and normal OSE cell lines. The 
2-D pI/mass maps were generated and used for interlysate comparison of protein 
expression between the different samples. Using this technique, we obtain pI, intact 
molecular weight and hydrophobicity of samples which provides us more information. 
This mass mapping methods can be used to classify ovarian serous carcinoma cell lines 
and the mass map can be used as a fingerprint for the proteome. The differential display 
map can show the presence of up- or down-regulated proteins, where some interesting 
differentially expressed proteins between IOSE80 and OVCA429 were identified by PMF 
as promising candidates of biomarkers. Identification of these markers should eventually 
















































































































145.76E+04P1114270877708995.4Heat shock cognate 71 kDa protein
361.99E+09P0578753621536755.5Keratin, type II cytoskeletal 8
205.14E+04P0578347966480585.3Keratin, type I cytoskeletal 18
412.94E+06P4610933800337776.3Crk-like protein
331.66E+04P3008522222222235.4UMP-CMP kinase
204.56E+04Q1304355447556315.0Serine/threonine protein kinase 4
302.54E+05P0872743998441065.0Keratin, type I cytoskeletal 19 
172.15E+04P35527-619885.1Keratin, type I cytoskeletal 9





































































44106441064410644106441065.0Keratin, type I cytoskeletal 19
47979479794797947979480585.3Keratin, type I cytoskeletal 18
51876518765187651876514185.5Keratin, type II cytoskeletal 7
53628536285362853628536755.5Keratin, type II cytoskeletal 8
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Figure 3.3 Comparisons of four serous carcinoma intact protein molecular weight 























































Figure 3.4 A differential display maps between the OVCA429 cell line and IOSE80 from 
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Differential Protein Mapping of Ovarian Serous Adenocarcinomas: Identification 
of Potential Markers for Distinct Tumor Stage 
4.1 Introduction 
Ovarian cancer remains the fifth leading cause of cancer deaths among women in 
the United States, with an estimated incidence of 22,220 and 16,210 deaths in 2005  (1). 
Five-year survival rates can be as high as 94% with early detection of the malignancy. 
However, as ovarian cancer is insidious in onset, less than 20% of ovarian tumors present 
at early stages of tumor development.  The 5-year survival of women with advanced 
stage ovarian cancer is approximately 28%, largely because existing therapies for 
widespread disease are rarely curative  (2).  Currently, the only marker with utility for 
therapeutic monitoring of ovarian cancer is CA125. However, CA125 does not possess 
sufficient specificity and sensitivity to have utility for patient screening, given that 
CA125 is elevated in 52.5% patients with low stage disease (3, 4) and detects only ~80% 
of all ovarian cancers  (5). Thus, additional diagnostic and prognostic markers for ovarian 
cancer are urgently needed.  Identification of novel ovarian cancer biomarkers may lead 
to the development of efficacious strategies for early detection, as well as improved 
monitoring of tumor progression and therapy. 
Epithelial ovarian cancers (carcinomas) occur as several distinct morphological 
subtypes, including serous, endometrioid, mucinous, and clear cell carcinomas. Each 
subtype of ovarian cancer has different clinical characteristics as well as different 
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molecular features and chemotherapeutic responsiveness (5-9). For ovarian serous 
carcinomas, a substantial body of literature supports the notion that low grade and high 
grade OSCs represent distinctly different tumors.  In particular, it is believed that the low 
grade OSCs likely arise from serous borderline tumors, while high grade OSCs likely 
arise de novo  (10).  Low grade OSCs are typically more indolent than the high grade 
neoplasms (11, 12), with the low grade neoplasm frequently pursuing a course that may 
last up to twenty years.  Although many patients with low grade OSCs may ultimately 
succumb due to widespread intra-abdominal spread of the tumor, the tumor maintains its 
low-grade appearance (13), in contrast to clinically aggressive high-grade neoplasms that 
spread rapidly and are usually associated with poor outcomes.  Molecular studies of 
OSCs show very distinct genetic alterations between low and high grade neoplasms, with 
the low grade/well differentiated ones having frequent K-Ras and/or B-Raf mutations in 
approximately 65% of the tumors and rarely showing p53 mutations, while high grade 
OSCs show p53 mutations in 50-80% of the cases  (14). 
Though comprehensive studies of tumor RNA and DNA have provided a number 
of insights into ovarian cancer pathogenesis, proteins are the major effector molecules in 
tumor cells.  Protein levels may be discordant with corresponding transcript levels and, 
importantly, a variety of post-translational modifications can have profound biological 
effects on protein function.  To date, a number of proteomics-based studies have been 
conducted on ovarian tumors or on sera obtained from patients with ovarian tumors using 
several methods, including 2-D PAGE  (15, 16), Surface Enhanced Laser Desorption 
Ionization (SELDI)  (17), and 2-D liquid-based separation methodologies (18, 19).  The 
latter methodology not only has greater reproducibility, but also has the ability to identify 
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and quantify proteins, and the capability to compare results amongst different sets of 
experiments and samples (20).  Histologic type-specific protein expression patterns in 
ovarian carcinomas have not been defined to date. 
We have compared protein expression in low stage (Stage 1) versus high stage 
(Stages 3/4) ovarian serous adenocarcinomas (OSCs) to identify stage-dependent protein 
expression. All but one of the tumors were high grade (grade 2 or 3), thus the observed 
expression differences between high and low stage tumors was not attributable to 
differences in the distribution of tumor grade (degree of differentiation) between the two 
groups.  We used a 2-dimensional liquid-based fractionation system to separate and map 
the protein expression of 19 OSCs from 15 different patients. We utilized hierarchical 
clustering analysis to explore tumor interrelationships based upon protein expression 
profiles. The tissues were classified into two groups, with one group consisting of low 
stage (Stage 1) tumors and another of high stage (Stages 3/4) tumors. Through the use of 
global protein expression profiling, a number of differentially expressed tumor-associated 
protein biomarkers with potential biological relevance in ovarian tumorigenesis or tumor 
progression were identified.  
4.2 Materials and Methods 
4.2.1 Samples and Preparation 
4.2.1.1 Samples  
Nineteen snap-frozen primary human ovarian serous carcinoma tissue samples 
obtained from patients seen at The University of Michigan Hospital were analyzed. 
Tumors were classified as well differentiated (grade 1), moderately differentiated (grade 
2), or poorly differentiated (grade 3) using standard criteria [16, 17]. Tumor stage (1–4) 
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was assigned according to FIGO criteria. Collection and analysis of human ovarian 
tumors was approved by the University of Michigan’s Institutional Review Board (IRB). 
The serous ovarian adenocarcinomas were histologically analyzed and staged by a Board-
Certified Pathologist (K.R.C.) prior to utilization in this study. 
4.2.1.2 Tissue lysis and buffer exchange  
All tumors were brought to the laboratory, and then promptly frozen and stored at 
-80ºC until analysis. Tissue samples were minced into small pieces on dry ice to prevent 
thawing and subsequently placed into 2-ml screw-cap microcentrifuge vials (BioSpec 
Products, OK) containing approximately 2/3 vial volume of minute glass beads (BioSpec 
Products). The vials were subsequently filled with 1ml lysis buffer (7.5 M urea, 2.5 M 
thiourea, 4% n-octyl-β-D-glucopyranoside (n-OG), 10 mM tris(2-carboxyethyl) 
phosphine (TCEP), 12.5% v/v glycerol, and 1% v/v protease inhibitor cocktail (Sigma, St. 
Louis, MO)). The tissue samples were homogenized for 3 min in a mini-bead beater cell 
disruptor, followed by centrifugation at 3000 x g for 10 min at room temp to pellet the 
bead mix. The supernatant containing tumor proteins were collected and stored on ice. In 
order to avoid incomplete tissue lysis and protein extraction, the vials were filled with 1 
ml fresh lysis buffer and again homogenized for 2 min as above. These two lysis 
solutions were combined in 10 mL polycarbonate centrifuge tubes and the insoluble 
material was removed by ultracentrifugation at 86,000 x g at 4ºC for 1h. The supernatant 
was collected and the buffer exchanged with the chromatofocusing start buffer using a 
PD-10 G-25 column (Amersham Biosciences, Piscataway, NJ). The proteins were 
quantified with the Bradford assay (Bio-Rad), and then the buffer-exchanged protein 




CF separation was performed on an HPCF-1D column (250 × 2.1 mm) (Beckman 
Coulter, Fullerton, CA) using the ProteomeLab™ PF2D protein fractionation system 
(Beckman Coulter), as described previously [18].  Two buffers were used to generate the 
pH gradient on the column. The SB solution was composed of 6M urea, 25mM Bis-Tris 
(pH 7.4). The EB solution was composed of 6M urea and 10% polybuffer74 (pH 4.0). 
Both buffer solutions were brought to pH by addition of a saturated solution of 
iminodiacetic acid. The CF column was pre-equilibrated with SB.  After equilibration, 
4.5 mg of proteins were loaded onto the CF column and the column was washed with 
100% SB to remove material that did not bind to the column at pH 7.4. Elution is 
achieved by applying a pH 4.0 elution buffer at a flow rate of 0.2 mL/min. The pH 
gradient was monitored on-line by a flow-through pH probe (Beckman Coulter). The UV 
absorbance of the eluent was monitored on-line at 280nm. The flow rate was 0.2ml/min, 
with 16 fractions in total being collected in 0.2 pH units in the range of pH 7.0 - 4.0. Each 
fraction was stored at -80°C until use.   
4.2.2.2 NPS-RP-HPLC with sample collection  
When the first-dimension separation was completed, the pI fractions collected 
from the first dimension were then separated by nonporous silica reverse phase HPLC 
(NPS-RP-HPLC) using a HPCF-2D (4.6 × 33 mm) NPS column (Beckman Coulter) and 
detected by absorbance at 214 nm using a Beckman model 166 UV absorption detector. 
The RP separation was performed at 0.75 mL/min and monitored at 214 nm using a 
Beckman 166 Model UV detector (Beckman-Coulter). Proteins eluting from the column 
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were collected by an automated fraction collector (Model SC 100, Beckman), controlled 
by an in-house designed DOS-based software program. To enhance the speed, resolution, 
and reproducibility of the separation, the RP column was heated to 65ºC by a column 
heater (Jones Chromatography, Model 7971, Resolution Systems, Holland, MI). Both 
mobile phase A: MilliQ® water (Millipore, Billerica, MA), and solvent B: acetonitrile 
(ACN) (Sigma) contains 0.1% v/v trifluoroacetic acid (TFA). The gradient was run from 
15 to 25% B in 1 min, 25 to 35% in 6 min, 35 to 38% in 4 min, 38 to 45% in 6 min, 45 to 
65% in 2 min, 65 to 67% in 6 min, and finally up to 100% in 1 min, then back to 5% in 1 
min. After the gradient, the column was washed by two fast gradients from 5% B to 
100% B in 5 min, 100% B back to 5% B in 1 min. Fractions from the HPLC eluent were 
collected using a semi-automated in-house program using a Model SC-100 fraction 
collector. Collected peak fractions were stored at -80ºC for further use. 
4.2.3 Protein Identification 
4.2.3.1 Tryptic Digestion Nonporous Reversed-Phase HPLC Fractions  
Second dimension fractions of interest (obtained from NPS-RP-HPLC) were 
concentrated to 20 µL with a SpeedVac concentrator (Labconco, Kansas City, MO) 
operating at 45ºC. Twenty microliters of 200 mM ammonium bicarbonate (Sigma) and 2 
µL of 100 mM dithiothreitol (DTT) (Sigma) were mixed with each concentrated sample 
to obtain a pH value of approximately 8.0. 0.5µL of L-1-tosylamido-2-phenylethyl 
chloromethylketone (TPCK) modified sequencing-grade porcine trypsin (Promega, 
Madison, WI) was vortexed prior to an overnight incubation at 37ºC, with agitation. 
Following incubation, 1µl TFA was added to each tube to halt digestion. 
4.2.3.2 MALDI-TOF-MS Sample Preparation and Data Acquisition  
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Before MALDI analysis, each tryptic digested sample was desalted and 
concentrated using C18 ZipTip (Millipore) into 5 µL 60% (v/v) ACN/0.1% (v/v) TFA. 
One microliter of the concentrated peptide mixture was spotted onto a Micromass 96-spot 
plate followed by 1 µL of matrix-standard layered on top of it. The MALDI matrix 
solution was prepared by diluting saturated α-CHCA (Sigma) solution with 60% v/v 
ACN and 0.1% v/v TFA at 1:4 ratio v/v with three internal standard proteins: angiotensin 
I (1296 Da), adrenocorticotropic hormone (ACTH clip 1–17, 2093 Da), and ACTH clip 
18–39 (2465 Da) (Sigma). 1 mg/mL standard proteins were diluted 100-fold with 
deionized water. These standards were further diluted 50, 40, and 30 times, respectively, 
with the diluted matrix. 
The Micromass TofSpec-2E™ (Waters) was used to generate peptide mass 
fingerprints (PMF), followed by database searching in the SwissProt database 10.30.2003. 
Spectra were calibrated using the internal calibrants to achieve a mass accuracy of less 
than 50 ppm. Monoisotopic peak lists were generated using Masslynx 4.0 and searched 
against the SwissProt protein database, using the MS-Fit search engine 10/20/2006 
(http://prospector.ucsf.edu/ucsfhtml4.0/msfit.htm). For the peak picking, we typically 
adjust the data threshold so the peaks will be around 60 to 100 for each spectrum with the 
internal standard peak excluded.  The search was performed using the following 
parameters: (1) species: human; (2) allowing one missed cleavage; (3) possible 
modifications: peptide N-terminal glutamine to pyroglutamic acid, oxidation of 
methionine, and protein N-terminus acetylated and phosphorylation of S, T and Y; (4) 
peptide mass tolerance 50 ppm; (5) MW ranged from 1000 to 100,000 Da; (6) pI range of 
protein 3–10. Protein identifications were considered confident matches when meeting 
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the following criteria: (i) ranked in the top three database hits; (ii) sequence coverage is 
>20%; (iii) average mass error is <50 ppm (iv) MOWSE scores over 104.  
4.2.3.3 QIT MALDI quadrupole ion trap-ToF Sample preparation and Data 
Acquisition  
Before MALDI analysis, each tryptic digested sample was desalted and concentrated 
using C18 ZipTip (Millipore) into 5 µL 60% (v/v) ACN/0.1% (v/v) TFA. 0.5 microliter 
of the concentrated peptide mixture was spotted onto a steel plate followed by 0.5 µL of 
matrix-standard layered on top of it. The MALDI matrix solution was prepared as 20 
mg/mL 2,5-dihydroxybenzonic acid (DHB) (LaserBio Labs, France) in 50% ACN with 
0.1% TFA. A pulsed N2 laser light (337 nm) with a pulse rate of 5 Hz was used for 
ionization. Each profile combines 2 laser shots. Argon was used as the collision gas for 
CID and helium was used for cooling the trapped ions. The TOF was externally 
calibrated using 1 pmol/µL of bradykinin fragment 1-7(757.40 m/z), angiotensin II 
(1046.54 m/z), P14R (1533.86 m/z) and 2 pmol/µL ACTH (2465.20 m/z) (sigma). Data 
were acquired on a Shimadzu Axima (MALDIQIT) (Manchester, UK). Acquisition and 
data processing were controlled by Launch-pad software V2.4.1 (Karatos, Manchester, 
UK). Monoisotopic peak lists were submitted to Swiss-Prot protein database 2006.06.20, 
using Mascot/peptide mass fingerprint search engine version 2.1 
(http://www.matrixscience.com/cgi/search_form.pl?FORMVER=2&SEARCH=PMF).  
The search was performed using the following parameters: (1) species: human; (2) 
trypsin; (3) allowing one missed cleavage; (4) peptide mass tolerance 1.2 Da, MS/MS 
tolerance 0.8Da; Protein identifications are considered confident matches when meeting 
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the following criteria: (1) Individual ions scores indicate the peptide identity or extensive 
homology; (2) At least two peptides matching.  
4.2.3.4 LC-MS/MS  
The tryptic-digested samples were separated by a capillary RP column (C18, 0.3 × 150 
mm) (Michrom Biosciences, Auburn, CA) on a Paradigm MG4 micropump (Michrom 
Biosciences) with a flow rate of 5 µL/min. The gradient, started at 5% ACN, was ramped 
to 60% ACN in 25 min and finally ramped to 95% in another 5 min. Both solvents A 
(water) and B (ACN) contain 0.3% formic acid. The resolved peptides were analyzed on 
a Finnigan LTQ mass spectrometer (Thermo Electron Corp., San Jose, CA) with an ESI 
ion source (Thermo). The capillary temperature was set at 175°C, spray voltage was 2.8 
kV, and capillary voltage was 30 V. The normalized collision energy was set at 35% for 
MS/MS. MS/MS spectra were searched using the SEQUEST algorithm, Version 27, 
incorporated in Bioworks software Rev. 3.1 SR1(Thermo) against the Swiss-Prot human 
protein database 2007.01.09. The search was performed using the following parameters: 
(1) database species, Homo sapiens; (2) allowing one missed cleavages; (3) possible 
modifications, none; (4) peptide ion mass tolerance 1.50 Da; (5) fragment ion mass 
tolerance 0.0 Da; (6) mass tolerance for precursor ions 1.40 Da; (7) peptide charges +1, 
+2, and +3. Protein identification was considered positive for a peptide with Xcorr of 
greater than or equal to 3.5 for triply, 2.5 for doubly, and 1.9 for singly charged ions. 
While no ions at higher charged states were considered. The search results that passed the 
criteria were subjected to be considered when ∆Cn ≥ 0.1. If multiple members of a 
protein family were identified, criteria used for selecting were as follows: (1) ranked 
preliminary score (Rsp) <5; (2) ions >70%; (3) at least 2 peptides matching; (4) if the 
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same spectrum matched different proteins, the higher Rsp, the higher ∆Cn, and/or ions 
>70% would be selected.  
4.2.4 Software 
The data from the 2-D liquid separations were displayed using the Mapping Tools 
Software Suite from Beckman-Coulter. The chromatographic UV data resulting from the 
NPS-RP-HPLC second-dimension separation of each pI fraction were analyzed by the 
ProteomeLab software to produce peak information (peak retention time, peak height, 
peak area). The Mapping Tools Software Suite imports the raw chromatogram intensity 
vs. retention time data and those processed peaks for each pI range in a data set.  The 
multiple data sets (one for each pI range as a "lane") were displayed as a two dimensional 
image based upon retention time versus pI range axis (termed a ProteoVue map).  Each 
raw chromatogram intensity and/or processed peak data value is shown proportional to 
color intensity or color value at its corresponding retention time and pI range location.   
Two such complete data sets or maps were compared.  Corresponding peaks in 
similar pI ranges were selected for comparison.   A DeltaVue difference map was 
prepared from the paired peaks. A single pI range can be compared across many data sets 
by creating a lane-band pattern image map.  One data set was defined as the Reference 
data set and the peaks in the Reference lane were paired with peaks in each of the 
individual Comparison data set's lane.  A MultiVue map was prepared for these paired 
peaks to allow comparison of many data sets at a specific pI value. 
4.2.5 Data analysis and clustering 
Data Standardization and Alignment: 
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The raw UV data for each sample were standardized to remove differences in the 
level and slope of the baseline. After standardization, the UV data for each pair of 
samples were aligned in order to maximize the local correlation coefficients between the 
aligned samples. The method used for the standardization and alignment was identical to 
that utilized previously [18].  
Comparisons: 
 To compare the overall pattern of protein expression in the samples, each pair was 
aligned separately, and then a correlation matrix was formed by calculating the Pearson 
correlation coefficient between each aligned pair of samples.  These correlation matrices 
were then visualized using a hierarchical clustering technique, thus producing a 
dendrogram in which pairs of points with greater correlation are linked sooner. Complete 
linkage clustering analysis was used to define the dendrograms. 
4.3 Results and Discussion 
4.3.1 Analysis of ovarian serous carcinoma samples 
Nineteen OSC tumor samples were used for proteomic analysis. Available 
clinico-pathological data associated with tumor specimens is provided in Table 1. 
Notably, all but one of the tumors were high grade (grade 2 or 3), so that expression 
differences between high and low stage tumors was not attributable to differences in the 
distribution of tumor grade (degree of differentiation) between the two groups.  Figure 1 
provides an overview of the experimental procedure. 2-D liquid-based mapping 
methodology was developed and applied to profile global protein expression of both low 
stage (stage 1) and high stage (stage 3/4) OSCs. A hierarchical clustering technique was 
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applied to classify the samples which were followed by the identification of differentially 
expressed proteins of different groups based on the classification. 
4.3.2 Proteome analysis 
  In this study, the global protein expression profiles for 19 OSC tissue samples (7 
stage 1 (from 5 individuals) and 12 stage 3/4 (from 10 individuals)) were generated using 
2-D liquid mapping methodology to assess protein expression differences between both 
low and high stage OSCs. Maps were produced using protein pI as the separation 
parameter in the first dimension and hydrophobicity, based upon reverse phase (RP)-
HPLC separation, in the second dimension. Protein detection in the first dimension was 
performed using UV absorption at 280 nm, with UV absorption at 214 nm in the second 
dimension.  Equal amounts of protein were loaded for each sample in order to generate 
the 2-D UV maps. As shown (Figure 2), 4.5 mg of tumor proteins were loaded onto the 
first dimension chromatofocusing column. In this figure each lane corresponds to a 
different pI value, and the bands correspond to the hydrophobicity as generated by the 
percentage of acetonitrile on the HPLC gradient at that pI. Each map consists of a total of 
15 pI fractions, corresponding to a pH range of 4.0-7.0.  
The chromatographic UV data resulting from the nonporous silica RP-HPLC 
second dimension separation of each pI fraction were displayed using ProteoVue 
software and analyzed to obtain peak information. The processed peaks were displayed in 
a 2-D “lane and band” format resulting in a highly detailed pI versus hydrophobicity 
protein expression map, using a color-coded format where color hue or its intensity is 
proportional to the relative quantitative UV peak volume of each peak, thus facilitating 
viewing of relationships or patterns within the complex chromatographic data set.  
 93
4.3.3 Reproducibility studies 
The reproducibility of the analysis technique was studied. Figure 3A represents 
the first dimension chromatofocusing profile for sample UM-OS-21-1, UM-OS-21-2 and 
UM-OS-21-3. Sample UM-OS-21-1 and UM-OS-21-2 are different protein lysates from 
the same tumor that were utilized for analysis of tumor heterogeneity. Sample UM-OS-
21-3 is the same sample as UM-OS-21-1, and was run twice for the first dimension 
chromatofocusing to explore experimental reproducibility. The second dimension 
hydrophobicity profiles for all pI fractions are shown in Fig. 3B. These results indicate 
high reproducibility between the chromatograms of the band patterns and retention times 
in both the first dimension chromatofocusing separation and the second dimension 
reverse phase liquid separation. Such reproducibility was observed in all the pI lanes 
separated for all three samples (data not shown). 
4.3.4 Hierarchical Clustering  
Complete linkage cluster analysis was performed following standardization and 
alignment. All pI fractions, from pH 4.0-7.0, were analyzed by this method. Total results 
were obtained by the average of all the fractions, and are shown in Figure 4A.   
In the dendrograms in Figure 4, the length and the subdivision of the branches 
display the relatedness of the cell lines and the expression of the proteins. The 
dendrogram illustrated in Figure 4A shows a major division in the distribution of 
different OSC tissue samples based upon respective protein expression using all protein 
fractions generated during the 2-D liquid mapping. In the rightmost major node (black 
dots), seven stage 1 OSC samples clustered together, with the three independent replicate 
OSC samples (UM-OS-021(1-3)) from the same patient clustering on the same node. In 
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the leftmost major node, the twelve stage 3/4 OSC tumor samples clustered together. Two 
independent sets of replicate tumor samples (UM-OS-7T/UM-OS-7Tb and UM-OS-014T 
(met 1 and met 2)) were found to cluster tightly together with the corresponding replicate 
OSC sample. However, upon analysis of individual fractions, differences in clustering 
patterns were noted.  Although all of the replicate OSC samples clustered tightly with the 
corresponding replicate sample from the same patient, thus indicating good 
reproducibility of the methodology, the difference between different stages was very 
apparent in the low pH fractions. Figure 4B represents the pH fraction from 4.4-4.6, with 
all the low stage tumors being grouped together, apart from the high stage tumors. The 
low and high stage tumors did not completely segregate in the pH fraction from 6.0-6.2 
based on their protein expression profiles (Figure 4C). Within this pH range, the 
expression profiles of five low stage OSCs were clustered with one high stage tumor 
(UM-OS-017Tb). All other high stage tumors clustered with two low stage tumors 
(CHTN-OS-041 and CHTN-OS-050). Thus, whereas protein profiling of all fractions 
simultaneously provided good segregation of high and low stage OSCs, protein profiling 
of individual fractions indicated that some low and high stage OSCs may have a similar 
protein expression profile.   
4.3.5 Stage-dependent Candidate Protein Markers of Ovarian Serous Carcinoma  
We next sought to identify proteins whose expression pattern could serve as 
potential stage-dependent biomarkers of OSC. In these comparisons between different 
stage samples, only peak areas that demonstrated at least 2-fold changes in quantitative 
protein expression were selected, and analyzed further by mass spectrometry. To 
individually identify the proteins in each peak, most of the proteins were identified using 
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LTQ analysis, with the data shown in Figure 5.  Additionally, some protein ID’s were 
confirmed using a MALDI-TOF MS or combined with QIT-MALDI-MS analysis (Data 
not shown. Peptide mapping fingerprints (PMF) were used for protein identification. The 
differentially expressed proteins that were identified are shown in Figure 5.  Each cell in 
the matrix represents the expression level of a single protein in a single sample, with red 
or orange indicating intensity above the medium and blue or dark blue indicating 
intensity below the median for that protein across all samples.  
 
Ratio =                                                                                            or 
 
Ratio =  
 
Upon protein identification, we found that more than one protein was confidently 
identified for some peaks. In these cases, a spectral counting-based quantitation method  
(24) was used. Using this method, we split the protein expression levels that were 
obtained from mapping tools between the identified proteins, based on the ratio of their 
quantitation. We also performed off-line ESI mass spectrometry on the LCT for sample 
UM-OS-007 fraction 4.6-4.4, with a peak retention time of 11 min to confirm the spectral 
counting-based quantitation method. As shown in Figure 6a, the proteins contained in this 
fraction were identified as Tumor Protein D54 and astrocytic phosphoprotein PEA-15. 
After spectrum deconvolution, we observed that the intensity of Tumor Protein D54 was 
1.71 × 102 and for astrocytic phosphoprotein PEA-15 the intensity was 1.42 × 102. For the 
spectral counting-based quantitation method, the numbers were 1189 and 1166, 
expression level of a single protein in stage 1
average expression level of proteins in stage 3 / 4
expression level of a single protein in stage 3 / 4
average expression level of proteins in stage 1
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respectively. Thus, the total expression levels were split for these two proteins based on 
the protein-protein ratio of 1.20. 
A subset of differentially expressed proteins was further evaluated as possible 
candidate biomarkers to distinguish between different stages in OSC samples. We 
focused on several proteins previously associated with cancer that displayed the largest-
fold change. The image in Figure 6A is displayed in a format with each different sample 
on the x-axis and hydrophobicity on the y-axis. The relative intensities of the peak are 
quantitatively proportional to the amount of corresponding protein detected by UV 
absorption. The leftmost six columns are samples from low stage tumors, while the 
rightmost twelve columns are samples from high stage tumors. The band circled in the 
picture shows high expression in the high stage tumors, but almost no expression in low 
stage tumors, and has been identified as containing both astrocytic phosphoprotein PEA-
15 and Tumor Protein D54. Tumor Protein D54 belongs to the TPD52 family, which 
consists of four members, TPD52 or D52, TPD52L1 or D53, and TPD52L2 or D54.  The 
Tumor Protein D52 (TPD52) gene was originally identified as being over-expressed in 
human breast carcinomas specifically within the neoplastic cells and was subsequently 
shown to encode a tumor-associated antigen in breast carcinoma through SEREX 
screening  (25). Tumor Protein D52 is known to be over-expressed in breast, prostate and 
ovarian carcinomas  (26,(27,(28,(29). Byrne et al (23) demonstrated that normal ovarian 
epithelium samples were predominantly TPD52-negative, whereas TPD52 was over-
expressed in most (44/57; 77%) ovarian carcinomas regardless of histological subtype. 
The encoded proteins are likely to function as adaptor proteins and to interact with D52-
like proteins and several other intracellular partner proteins  (30). We have shown that 
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Tumor Protein D54 is over-expressed in high stage OSC tumors, as compared to low 
stage tumors (Figure 6B). Figure 6C shows the tandem mass spectra of Tumor Protein 
D54-specific peptides. 
Vimentin, an intermediate filament protein, was significantly over-expressed in 
the high stage tumors as compared with the low stage tumors in our study (Figure 7A, 
7B). It is expressed in many hormone-independent mammary carcinoma cell lines.  
Vimentin is found in various cell types, especially mesenchymal cells. Previous reports 
have also demonstrated the increase of vimentin in the hyperplastic tissue compared to 
adjacent normal human prostatic epithelium  (31). Figure 7A shows vimentin expression 
(as indicated by UV absorption) and Figure 7B indicates protein expression levels for 
each of the individual tumors, sorted by stage. Figure 7C shows the tandem mass spectra 
of vimentin-specific peptides. 
Histone proteins were also found to be differentially expressed amongst low and 
high stage OSCs. Histone proteins are core components of nucleosome which wrap and 
compact DNA into chromatin, limiting DNA accessibility to the cellular machineries 
which require DNA as a template. Histones thereby play a central role in transcription 
regulation, DNA repair, DNA replication and chromosomal stability. Nucleosome 
remodeling is regulated via a complex set of post-translational modifications of histones. 
Acetylation of the lysine residues at the N-terminus of histone proteins removes positive 
charges, thus reducing the affinity between histones and DNA, and allowing for RNA 
polymerase and transcription factors to access the promoter region (Figure 8B).  Thus, 
histone acetylation enhances transcription while histone deacetylation represses 
transcription. We have found many histone proteins over-expressed in the high stage 
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tumors relative to low-stage tumors. Typically, histones have a very basic pI, usually 
above 11.  As we have found them with pI’s of less than 7, this suggests that these 
proteins may be heavily acetylated in the high stage tumors, thus shifting the pI of those 
proteins into our detection range, and which may suggest enhanced transcription in the 
high stage tumors.  Figure 8A shows the tandem mass spectra of a histone peptide with a 
two acetylation modification.   
4.3.6 Function of differentially expressed proteins 
A biological process clustering of differentially expressed proteins in low- versus 
high stage OSCs was created to analyze the distribution of important cellular regulatory 
functions. Based on a deregulation ratio threshold of +/- 2, we found 49 proteins over-
expressed in the high stage OSCs (Figure 9A) and 14 under-expressed proteins (Figure 
9B), with respect to the low stage tumors. Rather than being evenly distributed in all 
protein function categories, the over- and under-expressed proteins were clustered within 
specific biological processes.  The percentage of identified proteins in each assigned 
molecular function was calculated based on the number of assigned proteins over the 
total proteins. For the proteins that were over-expressed in the high stage tumors, 28% of 
identified proteins are involved in cytoskeletal organization, 19% are involved in 
transcription/translation, and 13%, 13%, 6%, 4% and 2% (respectively) are involved in 
cellular metabolism, response to stress, antioxidant, signal transduction or are 
mitochondria-related. 15% of the identified proteins have been classified as other (or 
unknown) function. For the under-expressed proteins, 0%, 7%, 33%, 7%, 0%, 20% and 
20% (respectively) are involved in cytoskeletal organization,  transcription/translation, 
cellular metabolism, response to stress, antioxidant, signal transduction or mitochondria-
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related. Proteins with other (or unknown) function are 13%. Notably, proteins involved in 
cytoskeleton organization or antioxidant pathways were found to be over-expressed in the 
high stage tumors relative to their proportion in the differentially expressed protein 
population. Interestingly, the mitochondria-related proteins that we have identified are 
clearly under-expressed in the high stage tumors, consistent with the study of Cuezva et 
al  (32) who showed that liver carcinogenesis involves a depletion of the cellular 
mitochondrial content, as revealed by reduced content of mitochondrial markers. 
Finally, of interest, the low stage OSC samples showed more protein in the acidic 
fractions and less protein in the basic fractions, as compared to high stage OSC samples.  
This phenomenon may result not only from changes in gene/protein expression, but also 
from alterations in the levels and types of post-translational modifications of expressed 
proteins (i.e., changes in acetylation and glycosylation, etc.), changes that are more 
difficult to ascertain on an individual basis, but can be observed globally by protein 
profiling. Thus, progress to define markers for diagnosis of low stage OSC may be 
facilitated by the establishment of protein profiles rather than by analysis of uniquely-
expressed proteins. 
4.4 Conclusion: 
In conclusion, we utilized 2-D liquid mapping and hierarchical clustering analysis 
of 19 OSC tissue samples (seven stage 1 (from 5 individuals) and twelve stage 3/4 (from 
10 individuals). Replicate samples obtained from the same tumor demonstrated good 
reproducibility in our analyses.  Further, we have demonstrated that the tumors could be 
classified in two groups, with one group associated with low stage OSCs and the others 
associated with high stage tumors. Notably, all but one of the tumors were high grade 
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(grade 2 or 3), so that expression differences between high and low stage tumors was not 
attributable to differences in the distribution of tumor grade (degree of differentiation) 
between the two groups.  To our knowledge such a systematic large-scale proteomic 
study has not before been achieved. With differential expression maps, 64 proteins were 
classified as over-expressed or under-expressed between the low and high stage OSCs. 
Further analysis of the differentially expressed proteins may facilitate identification of 
















































































Tumor ID Stage Grade Age 
UM-OS-001T 3 2 70 
UM-OS-002T 3c 2-3 40 
UM-OS-003T 4 3 56 
UM-OS-007T 3c 3 54 
UM-OS-007Tb 3c 3 54 
UM-OS-014 (met 1) 3c 3 54 
UM-OS-014 (met 2) 3c 3 54 
UM-OS-015T 4 3 49 
UM-OS-016T 3c 1 30 
UM-OS-017Tb 3c 2-3 81 
UM-OS-019T 3 3 44 
UM-OS-020T 3 3 65 
UM-OS-021-1T 1a 3 68 
UM-OS-021-2T  1a 3 68 
UM-OS-021-3T  1a 3 68 
CHTN-OS-004 1a 2 47 
CHTN-OS-041 1a 3 61 
CHTN-OS-050 1c 3 80 
























Figure 4.1 Experimental flow chart for global protein expression profiling maps. Tissue 
samples were lysed and the soluble proteins separated by pI in the first dimension using 
chromatofocusing, and by NPS-RP-HPLC in the second dimension. Data analysis was 
applied to the raw data and samples were grouped based on similarities in their protein 
expression using a hierarchical clustering analysis technique. Differential proteins were 

































































Figure 4.2 Ovarian cancer serous carcinoma tissue sample UM-OS-007 was separated 
using chromatofocusing over a pH range of 4.0–7.0, in 0.2 pH intervals, followed by 
separation in the second dimension using NPS RP-HPLC. The x-axis is pI of the 
chromatofocusing and the y-axis is hydrophobicity of the RP-HPLC. The scale of the 








































Figure 4.3 A. Analysis of technical reproducibility. Displayed is the first dimension 
chromatofocusing profile for sample UM-OS-21-1, UM-OS-21-2 and UM-OS-21-3. 
Sample UM-OS-21-1 and UM-OS-21-2 are different tissue samples from the same tumor 
that were used to study tumor heterogeneity. Sample UM-OS-21-3 is the same sample as 
UM-OS-21-1, and was run twice for chromatofocusing to explore experimental 
reproducibility. Total amount of each sample was 4.5mg, and the protein content of the 
samples was detected by UV absorption at 280nm. B. 2nd dimension separation was run 
continuously by NPS RP-HPLC for each CF separation. UV maps are shown. UV 
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Figure 4.4 Tissue samples were aligned separately and grouped based on similarities in 
their protein expression using complete linkage hierarchical clustering analysis. This 
technique produces a dendrogram in which pairs of points are joined sooner (i.e. closer to 
the ends of the dendrogram) if they have greater correlation. A. Dendrogram of samples 
showing overall similarity in protein expression profiles across the samples. B. pI fraction 
4.4-4.6 protein expression profiles across the samples C. pI fraction 6.0-6.2 protein 
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Figure 4.5 Differentially expressed proteins in stage I versus stage III/IV ovarian serous 
carcinoma tumors. Each cell in the matrix represents the expression level of a single 
protein in a single sample, with red or orange and blue or dark blue indicating intensity 










































Figure 4.6 A. Protein expression maps for a given pH fraction of all tumors analyzed for 
Tumor protein D54. B. Protein expression levels for Tumor protein D54 among all 
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Figure 4.7 A. Protein expression maps for a given pH fraction of all tumors analyzed for 
Vimentin. B. Protein expression levels for Vimentin among all tumors analyzed. C. LTQ 
analysis of several peptides identified as Vimentin. 
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Figure 4.8 Histone A. Histone peptide with a 2 acetylation modification.  B. Diagram 
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Figure 4.9 Distribution of identified proteins which are differentially expressed between 
low stage (stage I) and high stage (stage III/IV) tumors. A, over-expressed proteins in the 
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Lectin Affinity as an Approach to the Proteomic Analysis of Membrane 
Glycoproteins for Breast Cancer Cell Lines 
 
5.1 Introduction 
 Glycoproteins are proteins which have the attachment of specific carbohydrate 
structures which play a major role in determining protein function. Glycosylation 
alterations have been associated with the development and progression of cancer. A large 
number of clinical biomarkers and therapeutic targets in cancer are glycoproteins (1-5), 
such as CA125 in ovarian cancer, Her2/neu in breast cancer, and prostate-specific antigen 
(PSA) in prostate cancer. Monitoring glycoproteins could play an important role in 
detecting and evaluating tumor progression in addition to assessing tumor load and 
therapy.  
Lectins are proteins that specifically detect carbohydrate components and its 
specificity has provided the basis for probing different types of glycoconjugates in the 
cellular context. Lectin affinity chromatography has recently been widely used to purify 
glycoproteins (6-8) with specific structures and to examine their microheterogeneity to 
the level of a single sugar residue (9). 
Membrane proteins play critical roles in many biological functions and are often the 
molecular targets for drug discovery. Membrane proteins are often extensively 
glycosylated, especially those that decorate the extracellular membrane (4,7). Affinity 
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purification based on the properties of the glycoforms attached to these proteins has been 
used extensively to enrich membrane proteins (4,7).  
 In this work, we demonstrated the use of combining membrane extraction and 
lectin affinity column as a simple method to apply the proteomic analysis of membrane 
glycoproteins between two breast cancer cell lines CA1a and AT1. We first compared 
two different lysis methods for the membrane proteins extraction, then we applied lectin 
affinity extraction using ConA to extract the glycoproteome of these two cell lines. The 
protein expression between these two different cell lines was compared separately. A 
spectral count label-free method was applied for the quantitation of isolated membrane 
glycoproteins between these two cell lines. We could find differentially expressed 
proteins between these two different cell lines based on their glycoproteome expression 
to identify potential markers using this methodology.  
5.2 Experimental Section 
5.2.1 Cell Culture  
Fully malignant human breast cancer cells, MCF10CA1a cells and MCF10AT1 
cells were grown in monolayer on plastic in DMEM/F12 medium (1:1 mixture of DMEM 
and Ham’s F-12 medium) supplemented with 5% horse serum, 10 mg/mL of insulin, 20 
ng/mL epidermal growth factor, and 0.5 mg/mL of hydrocortisone. The cells were then 
collected by scraping and washed twice with PBS buffer before being stored at -80ºC. 
5.2.2 Lysis 
5.2.2.1 Lysis method 1 
The packed cells, which is around 0.2ml were suspended in 1.5ml of lysis buffer 
containing 10mM Tris-HCl, pH-7.5, 150 mM NaCl, 1% Nonidet P-40 and protease 
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inhibitor cocktail (Roche) for 30 min and use a tissue tearor (Biospec Products, Inc) for a 
total of 1 min in 15 s pulses with 30 s cooling periods after each pulse, the speed can 
reach to the 30,000 RPM. The lysate was centrifuged at 132 000 rpm for 30 min at 4°C, 
and the supernatant was collected and stored at -80 °C if not used immediately. Cell 
lysates were prefiltered, 0.45 ím filter (Millipore), prior to loading them on to columns. 
The final samples were subjected to quantitation by Bradford assay (Bio-Rad, Hercules, 
CA). 
5.2.2.2 Lysis method 2 – MEM-PER Eukaryotic membrane protein extraction 
reagent kit 
Totally300 µl of Reagent A were added to the cell pellet. We pipetted up and 
down to obtain a homogeneous cell suspension and then incubated for 10 minutes at 
room temperature with occasional vortexing. Lysed cells were place on ice. Two parts 
Reagent C was diluted with 1 part Reagent B which made sufficient mixture for each 
sample to receive 900 µl. The 900 µl diluted reagent C were added to each tube of lysed 
cells and vortexed. After that, tubes were incubated on ice for 30 minutes, vortexed every 
5 minutes. We centrifuged tubes at 10,000 x g for 3 minutes at 4°C and transferred 
supernatant to new tubes. Supernatant were incubated for 20 minutes at 37°C to separate 
the membrane protein fraction. Tubes were then centrifuge at room temperature for 2 
minutes at 10,000 x g to isolate the hydrophobic fraction from the hydrophilic fraction. 
Finally we carefully removed the hydrophilic phase (top layer) from the hydrophobic 
protein phase (bottom layer) and saved in a new tube. Perform the phase separations as 
quickly as possible because the interface between the layers slowly disappears at room 
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temperature. The final samples were subjected to quantitation by Bradford assay (Bio-
Rad, Hercules, CA). The samples were put into -80ºC freezer if not used. 
5.2.3 Lectin Affinity Glycoprotein Extraction.  
Agarose-bound Concanavalin A (ConA) were purchased from Vector 
Laboratories (Burlingame, CA). Agarose-bound 1 mL ConA were packed into disposable 
screw endcap spin columns with filters at both ends. The column was first washed with 3 
mL of binding buffer (20 mM Tris, 0.15 M NaCl, pH 7.4). Protease inhibitor stock 
solution was prepared by dissolving one complete EDTA-free protease inhibitor cocktail 
tablet (Roche, Indianapolis, IN) in 1 mL of H2O. The stock solution was added to the 
binding buffer and elution buffer at a ratio of (v/v) 1:50. Before running the lectin column, 
the lysate was diluted with 10 times binding buffer and concentrated to around 700ul 
using Microcon YM-10 (Millipore Corp., Bradford, MA) according to the manufacturer’s 
protocol. A 500µL sample diluted with 5mL of binding buffer was loaded onto the 
column and incubated for 15 min. The column was washed with 6 mL of binding buffer 
twice to wash off the nonspecific binding. The proteins were resuspended in binding 
buffer and then passed through the lectin affinity column. The captured glycoproteins 
were released with 10mL of elution buffer (0.3 M methyl-R-D-mannopyroside in 20 mM 
Tris and 0.5 M NaCl, pH 7.0). This step was repeated twice and the eluted fractions were 
pooled. The sample was concentrated using Microcon YM-10 (Millipore Corp., Bradford, 
MA) according to the manufacturer’s protocol to 400ul. The final eluted samples were 
subjected to quantitation by Bradford assay (Bio-Rad, Hercules, CA). 
5.2.4 Protein Digestion by Trypsin  
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Ten microliters of 50 mM ammonium bicarbonate (Sigma) was mixed with each 
concentrated 10 microliters sample to obtain pH 7.8. A 2 µL portion of 100 mM DTT 
(Sigma) was added and the resulting mixture incubated at 60 °C for 60 min. Another 180 
µL ammonium bicarbonate was added. TPCK modified sequencing grade porcine trypsin 
(1:50) (Promega, Madison, WI) was added and briefly vortexed prior to a 12-16 h 
incubation at 37 °C on an agitator. The digestion and reduction reaction was terminated 
by adding 1 µL of TFA to the digest.  
5.2.5 Mass Spectrometry. Protein Identification by LC-MS/MS.  
A Paradigm MG4 micropump (Michrom Biosciences Inc., Auburn, CA) was used 
for chromatographic separation of peptide mixtures. For nanoLC-ESI-MS/MS 
experiments, a nanotrap platform (Michrom) was set up prior to the electrospray source. 
It included a peptide nanotrap (0.2 × 50 mm2, Michrom) and a separation column (0.1 
mm × 150 mm, C18, Michrom). The peptide sample was injected and first desalted on 
the trap column with 3% solvent B (0.3% formic acid in 98% ACN) at 50 µL/min for 5 
min. The peptides were then eluted using a 45 min gradient from 5 to 95% B at a flow 
rate of 0.3 µL/min where solvent A was 0.3% formic acid in HPLC grade water. A 
Finnigan LTQ mass spectrometer (Thermo) was used to acquire spectra. A 75 µm metal 
spray tip (Michrom) was used, and spray voltage was set at 2.5 kV. The instrument was 
operated in data-dependent mode with dynamic exclusion enabled. The MS/MS spectra 
on the five most abundant peptide ions in full MS scan were obtained. The data 
acquisition and generation of peak list files were automatically done by Xcaliber software.  
5.2.6 Database Searching and Quantitation by Lable-free Spectral Count.  
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All MS/MS spectra were searched against the human protein database from 
SwissProt using SEQUEST algorithm incorporated in Bioworks software, version 3.1 
SR1 (Thermo Finnigan). Peptide fragment lists were generated and submitted to Swiss-
Prot database searching. The search parameters were as follows: (1) database species, 
Homo sapiens; (2) allowing two missed cleavages; (3) possible modifications, oxidation 
of M; (4) peptide ion mass tolerance 1.50 Da; (5) fragment ion mass tolerance 0.0 Da; (6) 
peptide charges +1, +2, and +3. The filter function in Bioworks browser was used to set a 
single threshold to consider fully tryptic peptides assigned with Xcorr values as follows: 
1.9 for singly charged ions, 2.5 for doubly charged ions, and 3.5 for triply charged ions, 
while no ions at higher charged states were considered. ∆Cn cutoff was set as 0.1. All 
SEQUEST search parameters and data filtering were the same in all digest fractions. 
Protein IDs were accepted if, and only if, the ID was positively identified in at least two 
MS/MS analyses. If the protein was identified by a single peptide matching, the spectrum 
was manually validated. The matched ions covering at least 70% of the peptide sequence 
must have a high signal-to- noise ratio (S/N). Two high S/N spectra of a single peptide 
matching protein were accepted for positive identification. Positive protein identification 
was validated by the Trans- Proteomics pipeline. This software includes both the 
PeptideProphet and ProteinProphet programs that were developed by Keller et al. 
(http://peptideprophet.sourceforge.net/). All the reported proteins have an identification 
probability higher than 90% and protein and peptide confidence above 90%. 
The spectral count is a mass spectrometry (MS)-based label-free quantitation 
approach. It counts the total number of MS/MS spectra taken on peptides from a given 
protein in a given LC/LC-MS/MS analysis. A number of studies have demonstrated a 
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high correlation between spectral count and protein abundances with the R square value 
around 0.99 (10) and is linearly correlated with the protein abundance over a dynamic 
range of 2 orders of magnitude. In addition, among three sampling statistics that are 
correlated with protein abundance (i.e spectral count, peptide count, sequence coverage) 
(11), spectral count method has the highest reproducibility and is the best performer in 
protein relative quantitation. We performed a comparative analysis between two  
samples using spectral count. Spectral count of individual proteins in both samples is  
acquired using DTASelect v2.0. All proteins with total spectral count less than 10 are  
considered absent and thus eliminated and confident proteins IDs are confirmed with the 
Trans- Proteomics pipeline analysis. The fold change based on spectral count is  
calculated followed by a t statistical test to examine the significant difference in  
protein spectral count between the two samples. All statistics calculation is performed  
in R which is a free software environment for statistical computing and graphics. A p-
value of 0.05 is used to determine whether a protein is differentially  
expressed or not.  
5.3 Results and Discussion 
5.3.1 Cell lines 
In this study, two cell lines were used. CA1a is a fully malignant human breast 
cancer cell line which rapidly forms invasive carcinomas with metastatic potential and 
displays histologic variations ranging from undifferentiated carcinomas to well 
differentiated adenocarcinomas (12). AT1 is a preneoplastic human breast cell line and 
this cell line forms preneoplastic lesions in nude mice that represent a premalignant stage 
with potential for neoplastic progression (13). 
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5.3.2 Comparison of Two Lysis Methods  
 In the present study, we investigated and compared the membrane glycoprotein 
extracted from two different lysis methods. In these experiments, around 3 × 107 AT1 and 
108 CA1a cells were used. Total cell lysates of CA1a and AT1 cells were passed through 
a Con A lectin column to capture oligomannosyl saccharides found in N-glycans (14,15). 
After ConA lectin extraction, the Bradford assay method was used for the quantitation of 
the membrane glycoproteins. The data are shown in Table 1. The proteins after lectin 
extraction correspond to a 150-200 fold average enrichment in the corresponding affinity 
purified proteins relative to the starting materials. In our studies, we found that the lysis 
method 1 provides improved recovery compared to the second lysis method. We also 
applied AT1 samples twice as AT1-1 and AT1-2 for the reproduciblility studies. Based 
on our results, we observe that the lysis method and lectin extraction are very 
reproducible. 
5.3.3 Protein Identification.  
Con A bound proteins were used prior mass spectrometric analysis. The lectin 
extracted proteins were digested by trypsin and analyzed by nano-LC/MS/MS. For each 
scan, the five most abundant peptides were sequenced. Figure 1A is a representative 
nano-LC/MS/MS base peak chromatogram, showing the detection of the more abundant 
ions across a 45 min gradient separation. Figure 1B shows a representative MS/MS 
spectrum of a peptide sequence from endoplasmin precursor, one of the N-linked 
glycoproteins as annotated in the Swiss-Prot database. Eighteen other ion peaks were also 
detected and assigned to this protein.  
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Tryptic digest fractions were analyzed. Positive protein identification was 
validated by the Trans- Proteomics pipeline. This software includes both the 
PeptideProphet and ProteinProphet programs that were developed by Keller et al. 
(http://peptideprophet.sourceforge.net/). All the reported proteins have an identification 
probability higher than 90% and 90% minimum peptide and protein probability.  
Common glycoproteins are listed in Table 2. Based on the data we obtained, they are all 
N-linked glycoproteins as annotated in the Swiss-Prot database. In terms of the 
subcellular location, around 50% are in the endoplasmic reticulum lumen. 
5.3.4 Analysis of Isolated Proteins from ConA for CA1a and AT1 
With the ConA lectin extraction, there was a total of 153 unique proteins and 515 
unique peptides were identified in CA1a and 104 unique proteins and 326 unique 
peptides in AT1. The distributions of the molecular weights and pI range of the isolated 
proteins are shown in Figure 2. For AT1 in Figure 2A, the molecular weights ranged 
from ~10 to ~180 kDa, which is very similar to the range with CA1a in Figure 2C. 
Similarly analysis of the pI values of these proteins in Figure 2B for AT1 and 2D for 
CA1a indicated the capacity to capture proteins with a wide range of values ranged from 
pH 4 to pH12. There did not appear to be any major differences in the molecular weight 
or pI ranges of the proteins selected by ConA. 
5.3.5 Differentially Expressed Glycoproteins Analysis. 
  We performed a comparative analysis between two samples using spectral count. 
Spectral count of individual proteins in both samples is acquired using DTASelect v2.0. 
All proteins with a total spectral count less than 10 are considered absent and thus 
eliminated and confident proteins IDs are confirmed with the Trans- Proteomics pipeline 
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analysis. The fold change based on spectral count is calculated followed by a t statistical 
test to examine the significant difference in protein spectral count between the two 
samples. All statistics calculations are performed in R. A p-value of 0.05 is used to 
determine whether a protein is differentially expressed. The differentially expressed 
glycoproteins with their fold change are shown in Table 3. The ratio here is a normalized 
ratio, that takes into account the variation between the total spectral count between the 
two samples, and it also adds 1.25 (correction factor) to every spectral count (such that no 
zero value occurs). The specific formula for the normalized ratio is:      
Rsc = log2[(n2+f)/(n1+f)] + log2[(t1-n1+f)/(t2-n2+f)] 
Highly differentially expressed proteins were further evaluated as possible 
candidate biomarkers to distinguish between CA1a and AT1. We focused on several 
proteins previously associated with cancer that displayed the largest-fold change. 
Gamma-glutamyl hydrolase is a lysosomal enzyme involved in the metabolism of folates 
and anti-folates and it plays a role as a tumor marker in breast and lung cancer (18). In 
our studies, we found that this protein only appears in CA1a and not in AT1 which is 
consistant with previous studies (19,20). The LC/MS/MS spectrum is shown in Figure 3. 
5.4 Conclusion 
 In this work, a fully malignant human breast cancer cell line CA1a and a 
preneoplastic human breast cell line AT1 were studied. We demonstrated the use of lectin 
affinity column as an approach for proteomic analysis of membrane glycoproteins. In our 
studies, we found that lysis method 1 is better than the membrane extract kit for our 
strategies. After lectin extraction,  it was shown that there was selective enrichment of 
proteins by the lectin affinity steps and both cell line samples have their own specific 
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glycoprotein expression patterns. However, there are few major differences in the pI or 
molecular weight ranges of the proteins selected by ConA for both the CA1a and AT1 
cell lines. Spectral count lable-free method was found to be a useful approach for the 
quantitation of isolated membrane glycoproteins between these two cell lines. 
Differentially expressed proteins identified between these two different cell lines could 
facilitate biomarker discovery. The use of lectin columns in conjunction with mass 
spectrometry offers a useful approach for the isolation and identification of novel 
glycoproteins. This work expands our tissue proteome capabilities from the analysis of 











































































































































N-linked (GlcNAc...)MembraneZinc transporter SLC39A7 KE4_HUMAN
N-linked (GlcNAc...)SecretedPlasma alpha-L-fucosidase precursor FUCO2_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenCollagen-binding protein 2 precursorSPH2_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulumNeutral alpha-glucosidase AB precursorGANAB_HUMAN
N-linked (GlcNAc...)Cell membraneEpithelial-cadherin precursorCADH1_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulumGlucosidase II beta subunit precursorGLU2B_HUMAN
N-linked (GlcNAc...)LysosomeBeta-hexosaminidase beta chain precursor HEXB_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenCalumenin precursorCALU_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenUDP-glucose:glycoprotein glucosyltransferase 1 precursorUGGG1_HUMAN
N-linked (GlcNAc...)LysosomeBeta-galactosidase precursorBGAL_HUMAN
N-linked (GlcNAc...)Cell membraneDesmoglein-2 precursorDSG2_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumen150 kDa oxygen-regulated protein precursorOXRP_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum membraneAspartyl\asparaginyl beta-hydroxylaseASPH_HUMAN
N-linked (GlcNAc...)LysosomeBeta-hexosaminidase alpha chain precursorHEXA_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenEndoplasmin precursorENPL_HUMAN
N-linked (GlcNAc...)Membrane4F2 cell-surface antigen heavy chain4F2_HUMAN
N-linked (GlcNAc...)Lysosome.Cathepsin D precursorCATD_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenReticulocalbin-1 precursorRCN1_HUMAN
N-linked (GlcNAc...)Cell membraneBasigin precursor BASI_HUMAN
N-linked (GlcNAc...)Endoplasmic reticulum lumenSulfatase-modifying factor 2 precursorSUMF2_HUMAN





























































































7.11E-10Glucosidase II beta subunit precursorGLU2B_HUMAN
1.11E-9Beta-hexosaminidasebeta chain precursor HEXB_HUMAN
0.925CalumeninprecursorCALU_HUMAN
0Desmoglein-2 precursorDSG2_HUMAN




2.04E-64F2 cell-surface antigen heavy chain4F2_HUMAN
0CathepsinD precursorCATD_HUMAN
5.55E-16Reticulocalbin-1 precursorRCN1_HUMAN



























Figure 5.1 LC/MS/MS analysis. (A) A representative nano-LC/MS/MS base peak 
chromatogram, showing the detection of the peptide ions across the 45 min gradient 
separation. (B) MS/MS sequencing data of a peptide from Endoplasmin precursor 
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Figure 5.2 Distribution of detected molecular weights and pI values of proteins 
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The Study of Humoral Response in Pancreatic Cancer Using modified Protein 
Microarrays from Panc-1 Cell-lysates 
 
6.1 Introduction 
Cancer is a class of diseases which is characterized by uncontrolled cell division 
and the ability of these cells to invade other tissues, either by direct growth into adjacent 
tissue (invasion) or by migration of cells to distant sites (metastasis). A total of 1,399,790 
new cancer cases and 564,830 deaths from cancer are expected in the United States in 
2006 (1). Among them, approximately 30,000 people die of pancreatic cancer each year. 
Pancreatic cancer is the third most common malignancy and the fifth leading cause of 
cancer-related mortality. The main reason for failing to achieve a cure in most patients is 
because the diagnosis of pancreatic cancer is rarely made at an early stage and most 
patients have incurable disease by the time they present with symptoms. The overall 5-
year survival rate for this disease is less than 5% (2). Early detecion is urgently needed. 
Proteomics studies and marker discovery can help for early detection. Currently, the 
markers for pancreatic cancer are Carbohydrate Antigen 19-9 (CA19-9) and 
carcinoembrionic antigen (CEA). However, false positives are a problem in the diagnosis 
(3). Thus, additional diagnostic and prognostic markers are needed.  Identification of 
novel biomarkers may lead to the development of efficacious strategies for early 
detection and improved therapy. 
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Protein microarray methodologies have the potential of revolutionizing the 
analysis of human cancer and have been explored for high-throughput screening of 
changes in protein expression include both antigen and antibody array formats (4-10). By 
simultaneously measuring the expression of thousands of proteins in clinical specimens, 
large numbers of data points can be collected to form a molecular fingerprint of a disease 
process. However, the traditional natural protein microarray methods sometimes can not 
provide sensitive immunoreactivity because of the complicated structure of proteins. As 
shown in Figure 2, the folded proteins may not have the immunoreactivity with the 
antibody because of the folded antigen. CNBr is a chemical used for protein digestion. It 
cleaves at Methionine and converts the Met into another amino acid called Homoserine 
lactone (HSL). Since methionine residues are not as abundant as other residues that are 
cleaved by popular enzymes, the proteins can be digested to larger pieces. By using 
digested proteins with larger resulting peptides on the microarray, we can take advantage 
of potentially immunogenic and biologically significant alterations to the proteins that 
may still be intact and detectable and increase the chance of the immunoreactivity 
between antigens and antibodies. The application of this modified protein microarray 
technology in the study of cancer will help the discovery, characterization, and clinical 
application of cancer biomarkers. 
 In this study, we applied a 2-D liquid separation method combined with modified 
microarray to study the classification of humoral response by exposing them to sera from 
normal individuals, chronic pancreatic patients and pancreatic cancer patients. This 
method involves separating intact proteins from cell lysates using chromatofocusing in 
the first dimension and separating proteins in a second dimension by nonporous silica 
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RP-HPLC. The result is a 2-D liquid phase fractionation of the proteins from the cell 
lysate. The fractionated proteins were digested by different digestion methods. The intact 
proteins and digested proteins can then be spotted on a nitrocellulose slide in parallel. 
This modified microarray method can be compared to the natural microarray method and 
used to study humoral response by exposing the arrays to sera from cancer patients, 
chronic pancreatic patients and normal individuals. Interesting spots which have different 
immunoreactivity can be identified using LC/MS/MS. 
6.2 Experimental Section 
6.2.1 Cell Culture and Sample Preparation  
6.2.1.1 Chemicals 
Acetonitrile, urea, thiourea, DTT, magnesium chloride, glycerol, bis-tris, 
trifluoroacetic acid, BSA and sodium dodecyl sulfate were obtained from Sigma (St. 
Louis, MO). Water was purified using a Milli-Q water filtration system (Millipore, Inc., 
Bedford, MA), and all solvents were HPLC grade unless otherwise specified. Reagents 
used were in the most pure form commercially available. Polybuffer 74 was purchased 
from Amersham Pharmacia Biotech (Piscataway, NJ). Anti-human IgG and Alexaflor647 
solution were obtained from Invitrogen (Carlsbad, CA). 1X PBS and ultrapure 
DNase/RNase free distilled water were obtained from Invitrogen Corp. (Carlsbad, CA). 
6.2.1.2 Sample Preparation. (a) Cell Culture 
The cells used in this work were from the pancreatic adenocarcinoma cell line, 
Panc-1. The cells were cultured in Dulbecco’s modified Eagle medium supplemented 
with 10% fetal bovine serum, 100 units/ml penicillin and 100 units/ml streptomycin 
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(Invitrogen, Carlsbad, CA). When the cells reached ~90% confluence, the cells were 
harvested with a cell scraper.  
6.2.1.2 (b) Cell Lysis 
Cell pellets were reconstituted in lysis buffer consisting of 7.5 M urea, 2.5 M 
thiourea, 4% n-octyl-β-D-glucopyranoside (n-OG), 10 mM tris(2-carboxyethyl) 
phosphine (TCEP), 12.5% v/v glycerol, and 1% v/v protease inhibitor cocktail (Sigma, St. 
Louis, MO). The cell pellets were lysed at room temperature for 1 h, followed by 
centrifugation at 35 000 rpm at 4 °C for 1 h. The supernatant were buffer exchanged into 
start buffer (6 M urea, 25 mM Bis-Tris, and 0.2% OG) using a PD-10 G-25 column 
(Amersham Biosciences, Piscataway, NJ) and stored at -80oC until further use. 
6.2.2 Separation 
6.2.2.1 Chromatofocusing 
CF separation was performed on an HPCF-1D column (250 × 2.1 mm) (Beckman 
Coulter, Fullerton, CA) using the ProteomeLab™ PF2D protein fractionation system 
(Beckman Coulter), as described previously  (11).  Two buffers were used to generate the 
pH gradient on the column. The SB solution was composed of 6M urea, 25mM Bis-Tris 
(pH 7.4). The EB solution was composed of 6M urea and 10% polybuffer74 (pH 4.0). 
Both buffer solutions were brought to pH by addition of a saturated solution of 
iminodiacetic acid. The CF column was pre-equilibrated with SB.  After equilibration, 
4.5 mg of proteins were loaded onto the CF column and the column was washed with 
100% SB to remove material that did not bind to the column at pH 7.4. Elution was 
achieved by applying a pH 4.0 elution buffer at a flow rate of 0.2 mL/min. The pH 
gradient was monitored on-line by a flow-through pH probe (Beckman Coulter). The UV 
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absorbance of the eluent was monitored on-line at 280nm. The flow rate was 0.2ml/min, 
with 16 fractions in total being collected in 0.2 pH units in the range of pH 7.0 - 4.0. Each 
fraction was stored at -80°C until use.   
6.2.2.2 NPS-RP-HPLC with sample collection  
When the first-dimension separation was completed, the pI fractions collected 
from the first dimension were separated by nonporous silica reverse phase HPLC (NPS-
RP-HPLC) using a ODSIII (4.6 × 33 mm) NPS column (Eprogen, Inc.) and detected by 
absorbance at 214 nm using a Beckman model 166 UV absorption detector. The RP 
separation was performed at 0.5 mL/min and monitored at 214 nm using a Beckman 166 
Model UV detector (Beckman-Coulter). Proteins eluting from the column were collected 
by an automated fraction collector (Model SC 100, Beckman), controlled by an in-house 
designed DOS-based software program. To enhance the speed, resolution, and 
reproducibility of the separation, the RP column was heated to 65ºC by a column heater 
(Jones Chromatography, Model 7971, Resolution Systems, Holland, MI). Both mobile 
phase A: MilliQ® water (Millipore, Billerica, MA), and solvent B: acetonitrile (ACN) 
(Sigma) contains 0.1% v/v trifluoroacetic acid (TFA). The gradient was run from 5% to 
15% in 1 min, 15% B to 25% in 2 min, 25% to 31% in 2 min, 31% to 41% in 10 min, 
41% to 47% in 6 min, 47% to 67% in 4 min, then up to 100% B in 3 min where it was 
held for 1 min, and then reduced to 5% in 1 min. After the gradient, the column was 
washed by two fast gradients from 5% B to 100% B in 5 min, 100% B back to 5% B in 1 
min. Fractions from the HPLC eluent were collected using a semi-automated in-house 
program using a Model SC-100 fraction collector. Collected peak fractions were stored at 
-80ºC for further use. 
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6.2.3 Protein Digest by CNBr 
 Collected fractions were then dried down and resuspended in 5µL deionized water, 
15µL TFA and 5µL 5M CNBr in ACN. Wrapped the tubes in aluminum foil and left 
them overnight at 4 ºC.  
6.2.4 Microarray Printing 
Fractionated proteins were transferred to 96-well printing plates (Bio-Rad) and 
were lyophilized to dryness. The fractions were then resuspended in printing buffer (62.5 
mM Tris-HCl (pH6.8), 1% w/v sodium dodecyl sulfate (SDS), 5% w/v dithiothreitol 
(DTT) and 1% glycerol in 1X PBS) and were left to shake overnight at 4oC. Slides were 
printed by transferring each fraction from the plate onto nitrocellulose slides using a non-
contact piezoelectric printer (Nanoplotter 2, GeSiM). Each spot resulted from deposition 
of 5 spotting events of 500 pL each, such that a total volume of 2.5 nL of each fraction 
was spotted. Each spot was found to be ~450 µm in diameter, with the distance between 
spots maintained at 600 µm. Printed slides were left on the printer deck overnight to dry 
and were then stored desiccated at 4oC until further use.  
6.2.5 Hybridization of slides 
The printed arrays were rehydrated in 1X PBS with 0.1% Tween-20 (PBS-T), and 
were then blocked overnight in a solution of 1% BSA in PBS-T.  Each serum sample was 
diluted 1:400 in probe buffer (5 mM magnesium chloride, 0.5 mM DTT, 0.05% Triton X-
100, 5% glycerol and 1% BSA in 1X PBS) to make a total solution of 4 mL and kept on 
ice. Each diluted serum sample was used to hybridize a slide for 2 hrs. Hybridization was 
done at 4oC in heat-sealable pouches with agitation, using a mini-rotator. The slides were 
then washed five times with probe buffer (5 min each), and were then hybridized with 4 
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mL anti-human IgG conjugated with Alexaflor647 (Invitrogen, Carlsbad, CA) (at 1 
µg/mL), for 1 hr at 4oC. After secondary incubation all slides were washed in probe 
buffer five times, for 5 min each, and were then dried by centrifugation for 10 min. All 
processed slides were immediately scanned using an Axon 4000B microarray scanner 
(Axon Instruments Inc., Foster City, CA) and GenePix Pro 6.0 software (Molecular 
Devices, Sunnyvale, CA) was used for data acquisition and analysis. 
6.2.6 Protein Identification 
Proteins were trypsin digested as described in other chapters. The tryptic-digested 
samples were separated by a capillary RP column (C18, 0.3 × 150 mm) (Michrom 
Biosciences, Auburn, CA) on a Paradigm MG4 micropump (Michrom Biosciences) with 
a flow rate of 300 nL/min. The gradient, started at 5% ACN, was ramped to 60% ACN in 
25 min and finally ramped to 95% in another 5 min. Both solvents A (water) and B (ACN) 
contained 0.3% formic acid. The resolved peptides were analyzed on A Finnigan LTQ 
mass spectrometer (Thermo Electron Corp., San Jose, CA) with a nanoESI ion source 
(Thermo). The capillary temperature was set at 175°C, spray voltage was 2.8 kV, and 
capillary voltage was 30 V. The normalized collision energy was set at 35% for MS/MS. 
MS/MS spectra were searched using the SEQUEST algorithm incorporated in Bioworks 
software (Thermo) against the Swiss-Prot human protein database. The search was 
performed using the following parameters: one miscleavage is allowed during the 
database search; Protein identification was considered positive for a peptide with Xcorr of 
greater than or equal to 3.5 for triply, 2.5 for doubly, and 1.9 for singly charged ions. 
6.3 Results and Discussion  
6.3.1 Proteome Studies 
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Figure 1 provides an overview of the experimental procedure. 2-D liquid-based 
mapping methodology was developed and applied to profile protein expression of Panc-1 
cell line. Cells were lysed in a urea buffer system and soluble proteins were separated by 
their isoelectric point (pI) using chromatofocusing in the first dimension. Equal amounts 
of protein were loaded for each run and a total of 15 pI fractions corresponding to a pH 
range of 4.0-7.0 were collected. The second dimension employed nonporous silica 
reverse-phase high performance liquid chromatography (NPS-RP-HPLC) to separate 
proteins according to their hydrophobicity. Eluent from the NPS-RP- HPLC step was 
collected. The collected fractions were separated to three parts, one part as intact protein; 
other two parts are digested using CNBr or Glu-C. The fractionated proteins or peptides 
were then arrayed on nitrocellulose slides as parallel unique spots. Hybridization of slides 
processed with sera from three diagnostic groups, normal sera, chronic pancreatitis and 
pancreaitc cancer sera. All processed slides were immediately scanned and data were 
analyzed to find interesting proteins which may serve as potential markers. Mass 
spectrometry (LC-MS/MS) was used for protein identification.  
6.3.2 Reproducibility studies 
The reproducibility of the analysis technique was studied. Figure 3A represents 
the first dimension chromatofocusing profile for four separate runs to explore 
experimental reproducibility (data only shows three). The second dimension 
hydrophobicity profiles for fractions 5.2-5.0 and 6.6-6.4 are shown in Fig. 3B. These 
results indicate high reproducibility between the chromatograms of the band patterns and 
retention times in both the first dimension chromatofocusing separation and the second 
dimension reverse phase liquid separation.  
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6.3.3 Microarray Image analysis 
Three sets of experiments were performed to probe the different digestion 
methods for the presence of tumor-reactive antibodies in the sera of prostate cancer 
patients, chronic pancreatitis and healthy patients. After 2-D liquid separation, the 
collected fractions were separated to three parts, one part as intact protein; other two parts 
are digested to peptides using CNBr or Glu-C. The fractionated proteins or peptides are 
then arrayed on nitrocellulose slides as parallel unique spots. GenePix Pro 6.0 software 
was used for data acquisition and analysis. Figure 4 shows a representative scanned 
image for a slide containing proteins fractionated in the pH range of 5.2-5.0 and 6.6-6.4 
which is probed with serum from healthy individuals. The green spots on the slide are the 
quality control for standards. The immunoreactivity between whole protein and digested 
proteins were compared in parallel. In the image, we can see that more spots light up for 
CNBr digest compared to the whole proteins which is consistent with our assumption that 
some of proteins do not shown the humoral response because of their complicated 
structures and the digested proteins can help to overcome this problem. All GluC digest 
spots light up which may due to the remaining GluC in solution which have nonspecific 
binding to the enzyme.  
We compared the levels of antibody binding for each of the fractions among the 
healthy sample, chronic pancreatic sample and cancer samples in order to identify those 
fractions most likely to contain cancer antigens. The yellow squares in the figure 
represent the spot for which immunoreactivity was not observed with this specific 
fraction when probed with serum from healthy subjects where it was seen for pancreatic 
cancer serum and chronic pancreatitis serum. This indicated the presence of auto-
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antibodies in serum from pancreatic cancer patients and chronic pancreatitis patients 
against specific cancer associated proteins. These fractions are also marked in Figure 3B 
as arrows and were identified using mass spectrometry (LC-MS/MS). The following 
criteria are used for the spots which are picked for these fractions. 1. the signal intensities 
equal or above 2 times the background 2. equal or above 50% of one group higher than 
the 2nd highest intensity from the other group are considered. Figure 5 is a representative 
of the spot in which immunoreactivity was observed in pancreatic cancer patients and 
chronic pancreatitis patients while not for normal individuals.  Scatter and box plots of 
signal intensities are shown for spot 762. The spot 762 is the fraction from pH 5.2-5.0 
and well numbered c6. The intensities of antibody binding are shown left as 1 for healthy 
patient, 2 in the middle for chronic pancreatitis and right as 3 for the pancreatic cancer. In 
the plot, each point is an individual sample. The dashed line in the left plot indicates the 
level of the second-highest healthy sample, which is defined as the threshold. The 
number 7 in figure indicates there are 7 cancer samples that are above this threshold. For 
chronic pancreatitis samples, there are 6 samples above this threshold. The box in the 
right plot indicates the upper and lower quartiles, with the line in the box indicating the 
median value. Our analysis indicates that there is a higher level of immunoreactivity in 
the cancer samples and chronic pancreatitis samples as compared to the normal samples 
for certain fractions and there is not a major difference between the cancer samples and 
chronic pancreatitis samples.  
6.4 Conclusion 
In this work, we applied a 2-D liquid separation method combined with a 
modified microarray approach to study the humoral response by exposing the arrays to 
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sera from normal individuals, chronic pancreatitis patients and pancreatic cancer patients. 
The proteins were separated based on their pI and hydrophobicity. CNBr and GluC 
digested proteins were compared with whole proteins from Panc-1 samples as baits for 
auto-antibodies in serum. Cancer, Pancreatitis and Normal sera were used for 
classification of response. Using this method, hundreds of isolated proteins in the liquid 
phase can be collected and digested for spotting on the microchip array. This method 
allows for comprehensive analysis of the cancer proteome using small amounts of analyte 
obtained by fractionation. The modified microarray method using CNBr digested proteins 
provided more sensitive results for microarray studies compared to the natural whole 
protein studies. Through the analysis, we found that for some interesting fractions, there 
is a higher level of immunoreactivity in the cancer samples and chronic pancreatitis 
samples compared to the normal samples. However, there are not major difference 
between cancer samples and chronic pancreatic samples. Further studies on fractions of 


























































































































































































































































Figure 6.3 Chromatofocusing and HPLC separation. 
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Figure 6.5 Scatter and box plots of signal intensities. 1 healthy patient, 2 chronic 
pancreatitis, 3 pancreatic cancer.  In the plot, each point is an individual sample. The 
dashed line indicates the level of the second-highest healthy sample, and the number 7 
there indicates the number of cancer samples above that threshold. The box indicates the 
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A two-dimensional liquid mapping method was used to map the protein 
expression of eight ovarian serous carcinoma cell lines and three immortalized ovarian 
surface epithelial cell lines. Maps were produced using pI as the separation parameter in 
the first dimension and hydrophobicity based upon reversed-phase HPLC separation in 
the second dimension. The method can be reproducibly used to produce protein 
expression maps over a pH range from 4.0 to 8.5. A dynamic programming method was 
used to correct for minor shifts in peaks during the HPLC gradient between sample runs. 
The resulting corrected maps can then be compared using hierarchical clustering to 
produce dendrograms indicating the relationship between different cell lines. It was found 
that several of the ovarian surface epithelial cell lines clustered together, whereas specific 
groups of serous carcinoma cell lines clustered with each other. Although there is limited 
information on the current biology of these cell lines, it was shown that the protein 
expression of certain cell lines is closely related to each other. Other cell lines, including 
one ovarian clear cell carcinoma cell line, two endometrioid carcinoma cell lines, and 
three breast epithelial cell lines, were also mapped for comparison to show that their 
protein profiles cluster differently than the serous samples and to study how they cluster 
relative to each other. In addition, comparisons can be made between proteins 
differentially expressed between cell lines that may serve as markers of ovarian serous 
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carcinomas. Some proteins which are differentially expressed between different groups 
were also identified with MALDI-TOF-MS to obtain finger print information combined 
with LCT-TOF-MS which provides information about intact molecular weight.  The 
automation of the method allows reproducible comparison of many samples, and the use 
of differential analysis limits the number of proteins that might require further analysis by 
mass spectrometry techniques 
An alternative 2-D liquid phase mass mapping strategy was also applied to profile 
protein expression of six ovarian serous carcinoma cell lines. Fractions collected from 
chromatofocusing every 0.15 pH unit were further separated by NPS-NP-HPLC and 
detected using on-line ESI-TOF. Fractions were collected and differentially expressed 
proteins were applied to MALDI-TOF-MS to identify the proteins. This method allows 
us to separate and map hundreds of proteins in the liquid phase which can be displayed in 
a 2-D image. For each protein, we can obtain information on the exact intact molecular 
weight, pI and hydrophobicity. Potential markers for specific groups can be identified. 
Classification can be also applied to different cell lines based on the mass mapping 
profile. Mass mapping methods can be used to classify ovarian cancer cell lines and can 
be used as a fingerprint of the proteome. This method may provide a means of studying 
proteins in interlysate comparisons over a large number of samples. 
The 2-dimensional liquid-based protein mapping method was used to characterize 
global protein expression patterns in 19 ovarian serous carcinoma tumor samples to 
facilitate molecular classification of tumor stage. Protein expression profiles were 
produced, using pI-based separation in the first dimension and hydrophobicity-based 
separation in the second dimension, over a pH range of 4.0-7.0. A hierarchical clustering 
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method was applied to protein maps to indicate the tumor interrelationships. The 19 
tumor samples could be classified into two different groups, one group associated with 
low stage (stage 1) tumors and the other group associated with high stage (stages 3/4) 
tumors. Proteins that were differentially expressed in different groups were selected for 
identification by MALDI-TOF-MS or QIT-TOF-MS/MS or LTQ-ESI-MS/MS. Fifteen of 
the selected proteins were over-expressed in the low stage tumors; 49 of the proteins were 
over-expressed in the high stage tumors. These proteins are known to play an important 
role in cellular functions such as glycolysis, protein biosynthesis, and cytoskeleton 
rearrangement and may serve as markers associated with different stages of ovarian 
serous carcinomas.  
In this work, a lectin affinity column was used as an approach to the proteomic 
analysis of membrane glycoproteins. We compared two different lysis methods and found 
out that lysis method 1 provides improved results compared to the commercial membrane 
extract kit. Both cell line samples we did have their own specific glycoprotein expression 
patterns for both ConA and WGA lectin affinity. We applied the spectral count label-free 
method for the quantification between CA1a and AT1 and identified differentially 
expressed proteins between them which may serve as potential markers. We found that 
N-linked glycoprotein gamma-glutamyl hydrolase only is expressed in the CA1a cell line 
consistent with the previous references. Further glycoprotein studies on cancer tissue 
samples could facilitate biomarker discovery. The use of lectin columns in conjunction 
with mass spectrometry offers a useful approach for the isolation and identification of 
novel glycoproteins. This work expands our tissue proteome capabilities from the 
analysis of soluble proteins in previous studies to the examination of membrane proteins. 
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              In other work, a two-dimensional liquid separation technique combined with 
modified microarray method was applied to study the classification of the humoral 
response response by exposing the arrays to sera from normal individuals, chronic 
pancreatitis patients and pancreatic cancer patients. After two dimensional separation 
according to the pI and hydrophobicity, the protein fractions were collected and different 
digestion methods were applied. The digested microarray fractions were applied to study 
the humoral response. The natural microarray method and modified microarray method 
was compared. We found that CNBr digest provided increased sensitivity compared with 
the whole proteins. The humoral response for cancer serum and pancreatic serum are 
different from the normal serum. The potential markers which have different 
immunoreactivity can be identified using the LC/MS/MS technique.  
In summary, the two-dimensional liquid differential mapping method combined 
with mass spectrometry has been provided a valuable means of analyzing complex 
biological systems by classifying different groups of human samples and identifying 
potential markers. This method has several advantages such as the ease of sample 
handling, automation, accurate molecular weight and better reproducibility for interlysate 
studies of the protein content of the cells. With the improvement of sensitivity of mass 
spectrometric instruments and the completion of the human genome sequence, this 
method has the potential of providing even lower detection limits, improved specificity 
and higher throughput for analysis of complex biosystems.  
